| Year |
Citation |
Score |
| 2024 |
Li JZ, Melberg M, Kittilson A, Abdel-Mohsen M, Li Y, Aga E, Bosch RJ, Wonderlich ER, Kinslow J, Giron LB, Di Germanio C, Pilkinton M, MacLaren L, Keefer M, Fox L, ... ... Mellors J, et al. Predictors of HIV rebound differ by timing of antiretroviral therapy initiation. Jci Insight. 9. PMID 38329130 DOI: 10.1172/jci.insight.173864 |
0.516 |
|
| 2023 |
Parikh UM, Penrose KJ, Heaps AL, Sethi R, Goetz BJ, Szydlo D, Chandran U, Palanee-Phillips T, Mgodi NM, Baeten JM, Mellors JW. HIV Drug Resistance Assessment among Women who Seroconverted during the MTN-025/HOPE Open-Label Extension Dapivirine Vaginal Ring Trial. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 37732881 DOI: 10.1097/QAI.0000000000003308 |
0.395 |
|
| 2023 |
Copertino DC, Holmberg CS, Weiler J, Ward AR, Howard JN, Levinger C, Pang AP, Corley MJ, Dündar F, Zumbo P, Betel D, Gandhi RT, McMahon DK, Bosch RJ, Linden N, ... ... Mellors JW, et al. The latency reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific CD8+ T-cells. Jci Insight. PMID 37581929 DOI: 10.1172/jci.insight.169028 |
0.333 |
|
| 2023 |
Botha JC, Demirov D, Gordijn C, Katusiime MG, Bale MJ, Wu X, Wells D, Hughes SH, Cotton MF, Mellors JW, Kearney MF, van Zyl GU. The largest HIV-1-infected T cell clones in children on long-term combination antiretroviral therapy contain solo LTRs. Mbio. e0111623. PMID 37530525 DOI: 10.1128/mbio.01116-23 |
0.517 |
|
| 2023 |
Nachega JB, Musoke P, Kilmarx PH, Gandhi M, Grinsztejn B, Pozniak A, Rawat A, Wilson L, Mills EJ, Altice FL, Mellors JW, Quinn TC. Global HIV control: is the glass half empty or half full? The Lancet. Hiv. PMID 37506723 DOI: 10.1016/S2352-3018(23)00150-9 |
0.5 |
|
| 2023 |
Nieves-Rosado HM, Jacobs JL, Naqvi A, Mellors JW, Macatangay BJ, Kane LP. Tim-3 signaling contributes to the suppressive capacity of Treg from people with HIV on antiretroviral therapy. Journal of Leukocyte Biology. PMID 37350502 DOI: 10.1093/jleuko/qiad068 |
0.399 |
|
| 2023 |
Sanders-Beer BE, Archin NM, Brumme ZL, Busch M, Deleage C, O'Doherty U, Hughes SH, Jerome K, Jones RB, Karn J, Kearney MF, Keele B, Kulpa D, Laird G, Li JZ, ... ... Mellors JW, et al. Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary. Aids Research and Human Retroviruses. PMID 37126090 DOI: 10.1089/AID.2022.0188 |
0.482 |
|
| 2023 |
Nachega JB, Scarsi KK, Gandhi M, Scott RK, Mofenson LM, Archary M, Nachman S, Decloedt E, Geng EH, Wilson L, Rawat A, Mellors JW. Long-acting antiretrovirals and HIV treatment adherence. The Lancet. Hiv. PMID 37062293 DOI: 10.1016/S2352-3018(23)00051-6 |
0.443 |
|
| 2023 |
Marzinke MA, Fogel JM, Wang Z, Piwowar-Manning E, Kofron R, Moser A, Bhandari P, Gollings R, Bushman LR, Weng L, Halvas EK, Mellors J, Anderson PL, Persaud D, Hendrix CW, et al. Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. Antimicrobial Agents and Chemotherapy. e0005323. PMID 36995219 DOI: 10.1128/aac.00053-23 |
0.481 |
|
| 2023 |
Hsu J, Van Besien K, Glesby MJ, Pahwa S, Coletti A, Warshaw MG, Petz L, Moore TB, Chen YH, Pallikkuth S, Dhummakupt A, Cortado R, Golner A, Bone F, Baldo M, ... ... Mellors JW, et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 186: 1115-1126.e8. PMID 36931242 DOI: 10.1016/j.cell.2023.02.030 |
0.402 |
|
| 2023 |
Gandhi RT, Bosch RJ, Mar H, Laird GM, Halvas EK, Hovind L, Collier AC, Riddler SA, Martin A, Ritter K, McMahon DK, Eron JJ, Cyktor JC, Mellors JW. Varied Patterns of Decay of Intact HIV-1 Proviruses Over two Decades of Art. The Journal of Infectious Diseases. PMID 36763044 DOI: 10.1093/infdis/jiad039 |
0.322 |
|
| 2023 |
Salata RA, Grinsztejn B, Ritz J, Collier AC, Hogg E, Gross R, Godfrey C, Kumarasamy N, Kanyama C, Mellors JW, Wallis CL, Hughes MD. Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance. Aids Research and Therapy. 20: 3. PMID 36604746 DOI: 10.1186/s12981-022-00494-9 |
0.377 |
|
| 2022 |
Tosiano MA, Mar H, Hoeth D, Eron JJ, Gandhi RT, McMahon DK, Bosch RJ, Mellors JW, Cyktor JC. Comparative sensitivity of automated (Abbott M2000) and manual plasma HIV-1 RNA PCR assays for the detection of persistent viremia after long-term antiretroviral therapy. Journal of Virus Eradication. 8: 100095. PMID 36479541 DOI: 10.1016/j.jve.2022.100095 |
0.465 |
|
| 2022 |
Steytler J, Craig C, van der Ryst E, Van Baelen B, Nuttall J, van Niekerk N, Mellors J, Parikh U, Wallis C. Characterization of Viruses in Phase III and Phase IIIb Trials (The Ring Study and DREAM) of the Dapivirine Vaginal Ring for HIV-1 Infection Risk Reduction. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 36345569 DOI: 10.1093/cid/ciac875 |
0.326 |
|
| 2022 |
Eshleman SH, Fogel JM, Halvas EK, Piwowar-Manning E, Marzinke MA, Kofron R, Wang Z, Mellors J, McCauley M, Rinehart AR, Clair MS, Adeyeye A, Hinojosa JC, Cabello R, Middelkoop K, et al. HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention. The Journal of Infectious Diseases. PMID 36240386 DOI: 10.1093/infdis/jiac415 |
0.564 |
|
| 2022 |
Parikh UM, Koss CA, Mellors JW. Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance? Current Hiv/Aids Reports. 19: 384-393. PMID 36112336 DOI: 10.1007/s11904-022-00616-y |
0.43 |
|
| 2022 |
Beesham I, Parikh UM, Mellors JW, Joseph Davey DL, Heffron R, Palanee-Phillips T, Bosman SL, Beksinska M, Smit J, Ahmed K, Makkan H, Selepe P, Louw C, Kotze P, Hofmeyr GJ, et al. High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study. Journal of Acquired Immune Deficiency Syndromes (1999). 91: 130-137. PMID 36094478 DOI: 10.1097/QAI.0000000000003027 |
0.553 |
|
| 2022 |
Avihingsanon A, Hughes MD, Salata R, Godfrey C, McCarthy C, Mugyenyi P, Hogg E, Gross R, Cardoso SW, Bukuru A, Makanga M, Badal-Aesen S, Mave V, Ndege BW, Fontain SN, ... ... Mellors JW, et al. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial. Journal of the International Aids Society. 25: e25905. PMID 36039892 DOI: 10.1002/jia2.25905 |
0.399 |
|
| 2022 |
Cyktor J, Qin S, Staines B, Nouraie M, Fitzpatrick M, Kessinger C, DeSensi R, Huang L, Rinaldo CR, Kingsley L, Tien PC, Mellors JW, Morris A. Associations of HIV persistence, cigarette smoking, inflammation, and pulmonary dysfunction in people with HIV on antiretroviral therapy. Medicine. 101: e29264. PMID 35801755 DOI: 10.1097/MD.0000000000029264 |
0.473 |
|
| 2022 |
Parikh UM, Mellors JW. How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention? Current Opinion in Hiv and Aids. 17: 213-221. PMID 35762376 DOI: 10.1097/COH.0000000000000746 |
0.528 |
|
| 2022 |
Ward AR, Thomas AS, Stevenson EM, Huang SH, Keating SM, Gandhi RT, McMahon DK, Bosch RJ, Macatangay BJ, Cyktor JC, Eron JJ, Mellors JW, Jones RB. No evidence that circulating HIV-specific immune responses contribute to persistent inflammation and immune activation in persons on long-term ART. Aids (London, England). PMID 35730388 DOI: 10.1097/QAD.0000000000003301 |
0.395 |
|
| 2022 |
Joseph KW, Halvas EK, Brandt LD, Patro SC, Rausch JW, Chopra A, Mallal S, Kearney MF, Coffin JM, Mellors JW. Deep Sequencing Analysis of Individual HIV-1 Proviruses Reveals Frequent Asymmetric Long Terminal Repeats. Journal of Virology. e0012222. PMID 35674431 DOI: 10.1128/jvi.00122-22 |
0.433 |
|
| 2022 |
Choudhary MC, Mellors JW. The transformation of HIV therapy: One pill once a day. Antiviral Therapy. 27: 13596535211062396. PMID 35492017 DOI: 10.1177/13596535211062396 |
0.36 |
|
| 2022 |
Levy L, Peterson JM, Kudrick LD, Chohan B, Bosek E, Mukui I, Mugambi M, Masyuko S, Mugurungi O, Ndlovu N, Mahaka I, Dunbar M, Hettema A, Kuwengwa RAP, Matse S, ... ... Mellors JW, et al. Casting a Wide Net: HIV Drug Resistance Monitoring in Pre-Exposure Prophylaxis Seroconverters in the Global Evaluation of Microbicide Sensitivity Project. Global Health, Science and Practice. 10. PMID 35487541 DOI: 10.9745/GHSP-D-21-00122 |
0.463 |
|
| 2022 |
Eshleman SH, Fogel JM, Piwowar-Manning E, Chau G, Cummings V, Agyei Y, Richardson P, Sullivan P, Haines CD, Bushman LR, Petropoulos C, Persaud D, Kofron R, Hendrix CW, Anderson PL, ... ... Mellors J, et al. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084. The Journal of Infectious Diseases. PMID 35301540 DOI: 10.1093/infdis/jiab576 |
0.505 |
|
| 2022 |
Ivison GT, Vendrame E, Martínez-Colón GJ, Ranganath T, Vergara R, Zhao NQ, Martin MP, Bendall SC, Carrington M, Cyktor JC, McMahon DK, Eron J, Jones RB, Mellors JW, Bosch RJ, et al. Natural Killer Cell Receptors and Ligands Are Associated With Markers of HIV-1 Persistence in Chronically Infected ART Suppressed Patients. Frontiers in Cellular and Infection Microbiology. 12: 757846. PMID 35223535 DOI: 10.3389/fcimb.2022.757846 |
0.499 |
|
| 2022 |
Bosch RJ, Gandhi RT, Mar H, Eron JJ, Cyktor JC, McMahon DK, Mellors JW. Associations between multiple measures of HIV-1 persistence on suppressive antiretroviral therapy. The Journal of Infectious Diseases. PMID 35137129 DOI: 10.1093/infdis/jiac030 |
0.509 |
|
| 2021 |
Parikh UM, Penrose KJ, Heaps AL, Halvas EK, Goetz BJ, Gordon KC, Hardesty R, Sethi R, Schwarzmann W, Szydlo DW, Husnik MJ, Chandran U, Palanee-Phillips T, Baeten JM, Mellors JW, et al. HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial. Journal of the International Aids Society. 24: e25833. PMID 34762770 DOI: 10.1002/jia2.25833 |
0.511 |
|
| 2021 |
Mellors JW, Guo S, Naqvi A, Brandt LD, Su L, Sun Z, Joseph KW, Demirov D, Halvas EK, Butcher D, Scott B, Hamilton A, Heil M, Karim B, Wu X, et al. Insertional activation of and by HIV-1 proviruses in T cell lymphomas. Science Advances. 7: eabi8795. PMID 34644108 DOI: 10.1126/sciadv.abi8795 |
0.428 |
|
| 2021 |
McMahon DK, Zheng L, Cyktor JC, Aga E, Macatangay BJ, Godfrey C, Para M, Mitsuyasu RT, Hesselgesser J, Dragavon J, Dobrowolski C, Karn J, Acosta EP, Gandhi RT, Mellors JW. A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy. The Journal of Infectious Diseases. 224: 648-656. PMID 34398236 DOI: 10.1093/infdis/jiaa777 |
0.491 |
|
| 2021 |
Hsu DC, Mellors JW, Vasan S. Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission? Frontiers in Immunology. 12: 710044. PMID 34322136 DOI: 10.3389/fimmu.2021.710044 |
0.527 |
|
| 2021 |
Brandt LD, Guo S, Joseph KW, Jacobs JL, Naqvi A, Coffin JM, Kearney MF, Halvas EK, Wu X, Hughes SH, Mellors JW. Tracking HIV-1-Infected Cell Clones Using Integration Site-Specific qPCR. Viruses. 13. PMID 34202310 DOI: 10.3390/v13071235 |
0.356 |
|
| 2021 |
SenGupta D, Brinson C, DeJesus E, Mills A, Shalit P, Guo S, Cai Y, Wallin JJ, Zhang L, Humeniuk R, Begley R, Geleziunas R, Mellors J, Wrin T, Jones N, et al. The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. Science Translational Medicine. 13. PMID 34162752 DOI: 10.1126/scitranslmed.abg3071 |
0.416 |
|
| 2021 |
Enick PN, Brooker JP, Tumiotto CM, Staines BT, Eron JJ, McMahon DK, Gandhi RT, Mellors JW, Sobolewski MD. Comparison of methods to quantify inducible HIV-1 outgrowth. Journal of Virus Eradication. 7: 100043. PMID 34136266 DOI: 10.1016/j.jve.2021.100043 |
0.462 |
|
| 2021 |
Li JZ, Aga E, Bosch R, Pilkinton M, Kroon E, MacLaren L, Keefer M, Fox L, Barr L, Acosta E, Anaworanich J, Coombs R, Mellors J, Landay A, Macatangay B, et al. Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 34117753 DOI: 10.1093/cid/ciab541 |
0.466 |
|
| 2021 |
Bale MJ, Katusiime MG, Wells D, Wu X, Spindler J, Halvas EK, Cyktor JC, Wiegand A, Shao W, Cotton MF, Hughes SH, Mellors JW, Coffin JM, Van Zyl GU, Kearney MF. Early Emergence and Long-Term Persistence of HIV-Infected T-Cell Clones in Children. Mbio. 12. PMID 33832973 DOI: 10.1128/mBio.00568-21 |
0.425 |
|
| 2021 |
Coffin JM, Bale MJ, Wells D, Guo S, Luke B, Zerbato JM, Sobolewski MD, Sia T, Shao W, Wu X, Maldarelli F, Kearney MF, Mellors JW, Hughes SH. Integration in oncogenes plays only a minor role in determining the in vivo distribution of HIV integration sites before or during suppressive antiretroviral therapy. Plos Pathogens. 17: e1009141. PMID 33826675 DOI: 10.1371/journal.ppat.1009141 |
0.417 |
|
| 2021 |
Nachega JB, Sam-Agudu NA, Mellors JW, Zumla A, Mofenson LM. Scaling Up Covid-19 Vaccination in Africa - Lessons from the HIV Pandemic. The New England Journal of Medicine. PMID 33789005 DOI: 10.1056/NEJMp2103313 |
0.347 |
|
| 2021 |
Baeten JM, Palanee-Phillips T, Mgodi NM, Mayo AJ, Szydlo DW, Ramjee G, Gati Mirembe B, Mhlanga F, Hunidzarira P, Mansoor LE, Siva S, Govender V, Makanani B, Naidoo L, Singh N, ... ... Mellors JW, et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. The Lancet. Hiv. 8: e87-e95. PMID 33539762 DOI: 10.1016/S2352-3018(20)30304-0 |
0.386 |
|
| 2021 |
Garcia-Bates TM, Palma ML, Anderko RR, Hsu DC, Ananworanich J, Korber BT, Gaiha GD, Phanuphak N, Thomas R, Tovanabutra S, Walker BD, Mellors JW, Piazza PA, Kroon E, Riddler SA, et al. Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. Ebiomedicine. 63: 103175. PMID 33450518 DOI: 10.1016/j.ebiom.2020.103175 |
0.483 |
|
| 2021 |
Hikichi Y, Van Duyne R, Pham P, Groebner JL, Wiegand A, Mellors JW, Kearney MF, Freed EO. Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations. Mbio. 12. PMID 33436439 DOI: 10.1128/mBio.03134-20 |
0.511 |
|
| 2021 |
Stevenson EM, Ward AR, Truong R, Thomas AS, Huang SH, Dilling TR, Terry S, Bui JK, Mota TM, Danesh A, Lee GQ, Gramatica A, Khadka P, Conce Alberto WD, Gandhi RT, ... ... Mellors JW, et al. HIV-specific T-cell responses reflect substantive in vivo interactions with antigen despite long-term therapy. Jci Insight. PMID 33400687 DOI: 10.1172/jci.insight.142640 |
0.5 |
|
| 2020 |
Crowell TA, Ritz J, Coombs RW, Zheng L, Eron JJ, Mellors JW, Dragavon J, van Zyl GU, Lama JR, Ruxrungtham K, Grinsztejn B, Arduino RC, Fox L, Ananworanich J, Daar ES, et al. Novel Criteria for Diagnosing Acute and Early HIV Infection in a Multi-National Study of Early Antiretroviral Therapy Initiation. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 33382405 DOI: 10.1093/cid/ciaa1893 |
0.475 |
|
| 2020 |
McMahon DK, Zheng L, Cyktor JC, Aga E, Macatangay BJ, Godfrey C, Para M, Mitsuyasu RT, Hesselgesser J, Dragavon J, Dobrowolski C, Karn J, Acosta EP, Gandhi RT, Mellors JW, et al. A phase I/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 expression (A5315). The Journal of Infectious Diseases. PMID 33349862 DOI: 10.1093/infdis/jiaa777 |
0.492 |
|
| 2020 |
McCormick KD, Mellors JW, Jacobs JL. Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2. Current Opinion in Hiv and Aids. PMID 33186228 DOI: 10.1097/COH.0000000000000656 |
0.514 |
|
| 2020 |
Mallarino-Haeger C, Abebe KZ, Jackson EK, Zyhowski A, Klamar-Blain C, Cyktor JC, Comer D, Brand RM, Gillespie DG, Holleran K, Mellors JW, McGowan I, Riddler SA, Macatangay BJC. Brief Report: Dipyridamole Decreases Gut Mucosal Regulatory T-Cell Frequencies Among People With HIV on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999). 85: 665-669. PMID 33177477 DOI: 10.1097/QAI.0000000000002488 |
0.425 |
|
| 2020 |
Riddler SA, Para M, Benson CA, Mills A, Ramgopal M, DeJesus E, Brinson C, Cyktor J, Jacobs J, Koontz D, Mellors J, Laird GM, Wrin T, Patel H, Guo S, et al. Vesatolimod, a toll-like receptor 7 agonist, induces immune activation in virally suppressed adults with HIV-1. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 33043969 DOI: 10.1093/cid/ciaa1534 |
0.343 |
|
| 2020 |
Halvas EK, Joseph KW, Brandt LD, Guo S, Sobolewski MD, Jacobs JL, Tumiotto C, Bui JK, Cyktor JC, Keele BF, Morse GD, Bale MJ, Shao W, Kearney MF, Coffin JM, ... ... Mellors JW, et al. HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. The Journal of Clinical Investigation. PMID 33016926 DOI: 10.1172/JCI138099 |
0.485 |
|
| 2020 |
Jacobs JL, Tosiano MA, Koontz DL, Staines B, Worlock A, Harrington K, Bakkour S, Stone M, Shutt K, Busch MP, Mellors JW. Automated, Multi-Replicate Quantification of Persistent HIV-1 Viremia in Individuals on Antiretroviral Therapy. Journal of Clinical Microbiology. PMID 32967899 DOI: 10.1128/JCM.01442-20 |
0.438 |
|
| 2020 |
Gandhi RT, Cyktor JC, Bosch RJ, Mar H, Laird GM, Martin A, Collier AC, Riddler SA, Macatangay BJ, Rinaldo CR, Eron JJ, Siliciano JD, McMahon DK, Mellors JW. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. The Journal of Infectious Diseases. PMID 32823274 DOI: 10.1093/Infdis/Jiaa532 |
0.594 |
|
| 2020 |
Simonetti FR, White JA, Tumiotto C, Ritter KD, Cai M, Gandhi RT, Deeks SG, Howell BJ, Montaner LJ, Blankson JN, Martin A, Laird GM, Siliciano RF, Mellors JW, Siliciano JD. Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. Proceedings of the National Academy of Sciences of the United States of America. PMID 32690683 DOI: 10.1073/Pnas.2006816117 |
0.588 |
|
| 2020 |
Cyktor JC, Bosch RJ, Mar H, Macatangay BJ, Collier AC, Hogg E, Godfrey C, Eron JJ, McMahon DK, Mellors JW, Gandhi RT. Male sex and obesity are associated with residual plasma HIV-1 viremia in persons on long-term antiretroviral therapy. The Journal of Infectious Diseases. PMID 32603416 DOI: 10.1093/Infdis/Jiaa373 |
0.531 |
|
| 2020 |
Stone M, Rosenbloom D, Bacchetti P, Deng X, Dimapasoc M, Keating S, Bakkour S, Richman D, Mellors J, Deeks S, Lai J, Beg S, Siliciano J, Pagliuzza A, Chomont N, et al. Assessing suitability of next-generation viral outgrowth assays as proxies for classic QVOA to measure HIV-1 latent reservoir size. The Journal of Infectious Diseases. PMID 32147687 DOI: 10.1093/Infdis/Jiaa089 |
0.511 |
|
| 2020 |
McCormick KD, Penrose KJ, Brumme CJ, Harrigan R, Viana RV, Mellors JW, Parikh UM, Wallis CL. Discordance between Etravirine Phenotype and Genotype-based Predicted Phenotype for Subtype C HIV-1 from First-line Antiretroviral Therapy Failures in South Africa. Antimicrobial Agents and Chemotherapy. PMID 32071061 DOI: 10.1128/Aac.02101-19 |
0.572 |
|
| 2020 |
Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, et al. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. The Lancet. Hiv. PMID 32035041 DOI: 10.1016/S2352-3018(19)30400-X |
0.343 |
|
| 2019 |
Katusiime MG, Halvas EK, Wright I, Joseph K, Bale MJ, Kirby-McCullough B, Engelbrecht S, Shao W, Hu WS, Cotton MF, Mellors JW, Kearney MF, van Zyl GU. Intact HIV proviruses persist in children 7-9 years after initiation of ART in the first year of life. Journal of Virology. PMID 31776265 DOI: 10.1128/Jvi.01519-19 |
0.418 |
|
| 2019 |
Patro SC, Brandt LD, Bale MJ, Halvas EK, Joseph KW, Shao W, Wu X, Guo S, Murrell B, Wiegand A, Spindler J, Raley C, Hautman C, Sobolewski M, Fennessey CM, ... ... Mellors JW, et al. Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. Proceedings of the National Academy of Sciences of the United States of America. PMID 31776247 DOI: 10.1073/Pnas.1910334116 |
0.527 |
|
| 2019 |
Wallis CL, Hughes MD, Ritz J, Viana R, Silva de Jesus C, Saravanan S, van Schalkwyk M, Mngqibisa R, Salata R, Mugyenyi P, Hogg E, Hovind L, Wieclaw L, Gross R, Godfrey C, ... ... Mellors JW, et al. Diverse HIV-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line ART in Resource Limited Settings. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31724034 DOI: 10.1093/Cid/Ciz1116 |
0.512 |
|
| 2019 |
Jacobs JL, Halvas EK, Tosiano MA, Mellors JW. Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms. Frontiers in Microbiology. 10: 2383. PMID 31681237 DOI: 10.3389/Fmicb.2019.02383 |
0.568 |
|
| 2019 |
Macatangay BJC, Gandhi RT, Brad Jones R, Mcmahon DK, Lalama CM, Bosch RJ, Cyktor JC, Thomas AS, Borowski L, Riddler SA, Hogg E, Stevenson E, Eron JJ, Mellors JW, Rinaldo CR, et al. PD-1HI T cells are associated with lower hiv-specific immune responses despite long-term antiretroviral therapy. Aids (London, England). PMID 31634201 DOI: 10.1097/Qad.0000000000002406 |
0.477 |
|
| 2019 |
Musick A, Spindler J, Boritz E, Pérez L, Crespo-Vélez D, Patro SC, Sobolewski MD, Bale MJ, Reid C, Keele BF, Capoferri A, Shao W, Wiegand A, Simonetti FR, Mellors JW, et al. HIV Infected T Cells Can Proliferate Without Inducing Expression of the Integrated Provirus. Frontiers in Microbiology. 10: 2204. PMID 31632364 DOI: 10.3389/Fmicb.2019.02204 |
0.507 |
|
| 2019 |
Shao W, Shan J, Hu WS, Halvas EK, Mellors JW, Coffin JM, Kearney M. HIV Proviral Sequence Database (PSD): A New Public Database for Near Full-Length HIV Proviral Sequences and Their Meta-Analyses. Aids Research and Human Retroviruses. PMID 31502467 DOI: 10.1089/Aid.2019.0214 |
0.584 |
|
| 2019 |
Boltz VF, Shao W, Bale MJ, Halvas EK, Luke B, McIntyre JA, Schooley RT, Lockman S, Currier JS, Sawe F, Hogg E, Hughes MD, Kearney MF, Coffin JM, Mellors JW. Linked dual-class HIV resistance mutations are associated with treatment failure. Jci Insight. PMID 31487271 DOI: 10.1172/Jci.Insight.130118 |
0.521 |
|
| 2019 |
Veldsman KA, Janse van Rensburg A, Isaacs S, Naidoo S, Laughton B, Lombard C, Cotton MF, Mellors JW, van Zyl GU. HIV-1 DNA decay is faster in children who initiate ART shortly after birth than later. Journal of the International Aids Society. 22: e25368. PMID 31441231 DOI: 10.1002/Jia2.25368 |
0.521 |
|
| 2019 |
Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugyenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, ... ... Mellors JW, et al. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study. The Lancet. Hiv. PMID 31371262 DOI: 10.1016/S2352-3018(19)30146-8 |
0.368 |
|
| 2019 |
McManus WR, Bale MJ, Spindler J, Wiegand A, Musick A, Patro SC, Sobolewski MD, Musick VK, Anderson EM, Cyktor JC, Halvas EK, Shao W, Wells D, Wu X, Keele BF, ... ... Mellors JW, et al. HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. The Journal of Clinical Investigation. 130. PMID 31361603 DOI: 10.1172/Jci126714 |
0.371 |
|
| 2019 |
Bedimo RJ, Mar H, Bosch RJ, Drechsler H, Cyktor JC, Macatangay BJC, Lalama C, Rinaldo C, Collier A, Godfrey C, Hogg E, Hensel C, Eron JJ, Mcmahon DK, Mellors JW, et al. No Evidence for an Association between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 31335587 DOI: 10.1097/Qai.0000000000002124 |
0.455 |
|
| 2019 |
Spudich S, Robertson KR, Bosch RJ, Gandhi RT, Cyktor JC, Mar H, Macatangay BJ, Lalama CM, Rinaldo C, Collier AC, Godfrey C, Eron JJ, McMahon D, Jacobs JL, Koontz D, ... ... Mellors JW, et al. Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. The Journal of Clinical Investigation. 130. PMID 31305262 DOI: 10.1172/Jci127413 |
0.573 |
|
| 2019 |
Macatangay BJC, Jackson EK, Abebe KZ, Comer D, Cyktor J, Klamar-Blain C, Borowski L, Gillespie DG, Mellors JW, Rinaldo CR, Riddler SA. A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Hiv-Associated Chronic Inflammation. The Journal of Infectious Diseases. PMID 31282542 DOI: 10.1093/Infdis/Jiz344 |
0.472 |
|
| 2019 |
Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, et al. Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903/AMC-080 trial. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 31279752 DOI: 10.1016/J.Bbmt.2019.06.033 |
0.398 |
|
| 2019 |
Coffin JM, Wells DW, Zerbato JM, Kuruc JD, Guo S, Luke BT, Eron JJ, Bale M, Spindler J, Simonetti FR, Hill S, Kearney MF, Maldarelli F, Wu X, Mellors JW, et al. Clones of infected cells arise early in HIV-infected individuals. Jci Insight. 4. PMID 31217357 DOI: 10.1172/Jci.Insight.128432 |
0.563 |
|
| 2019 |
Chimukangara B, Lessells RJ, Rhee SY, Giandhari J, Kharsany ABM, Naidoo K, Lewis L, Cawood C, Khanyile D, Ayalew KA, Diallo K, Samuel R, Hunt G, Vandormael A, Stray-Pedersen B, ... ... Mellors JW, et al. Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis. Eclinicalmedicine. 9: 26-34. PMID 31143879 DOI: 10.1016/J.Eclinm.2019.03.006 |
0.555 |
|
| 2019 |
Glaubius R, Ding Y, Penrose KJ, Hood G, Engquist E, Mellors JW, Parikh UM, Abbas UL. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. Journal of the International Aids Society. 22: e25282. PMID 31074936 DOI: 10.1002/Jia2.25282 |
0.48 |
|
| 2019 |
Keating SM, Jones RB, Lalama CM, Bosch RJ, McMahon D, Hampton D, Cyktor J, Eron JJ, Mellors JW, Busch MP, Gandhi RT. HIV Antibodies Decline During Antiretroviral Therapy but Remain Correlated with HIV DNA and HIV-specific T Cell Responses. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 31045647 DOI: 10.1097/Qai.0000000000002080 |
0.603 |
|
| 2019 |
Rosenbloom DIS, Bacchetti P, Stone M, Deng X, Bosch RJ, Richman DD, Siliciano JD, Mellors JW, Deeks SG, Ptak RG, Hoh R, Keating SM, Dimapasoc M, Massanella M, Lai J, et al. Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. Plos Computational Biology. 15: e1006849. PMID 30978183 DOI: 10.1371/Journal.Pcbi.1006849 |
0.434 |
|
| 2019 |
Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, ... ... Mellors JW, et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting. The Lancet. Hiv. PMID 30885693 DOI: 10.1016/S2352-3018(19)30052-9 |
0.509 |
|
| 2019 |
Hsu DC, Mellors JW. Longitudinal changes in HIV DNA in HIV controllers: what do they mean? Journal of the International Aids Society. 22: e25254. PMID 30768753 DOI: 10.1002/Jia2.25254 |
0.575 |
|
| 2019 |
Zerbato JM, McMahon DK, Sobolewski MD, Mellors JW, Sluis-Cremer N. Naïve CD4+ T Cells Harbor a Large Inducible Reservoir of Latent, Replication-Competent HIV-1. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30753360 DOI: 10.1093/Cid/Ciz108 |
0.521 |
|
| 2019 |
Bui JK, Cyktor JC, Fyne E, Campellone S, Mason SW, Mellors JW. Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART. Plos One. 14: e0211112. PMID 30682108 DOI: 10.1371/Journal.Pone.0211112 |
0.463 |
|
| 2019 |
Tosiano MA, Jacobs JL, Shutt KA, Cyktor JC, Mellors JW. A Simpler and More Sensitive Single Copy HIV-1 RNA Assay to Quantify Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy. Journal of Clinical Microbiology. PMID 30626659 DOI: 10.1128/Jcm.01714-18 |
0.557 |
|
| 2019 |
Michael Bale J, Valerie Boltz F, Mellors JW, Coffin JM, Hughes SH, Kearney MF. A12 Modeling residual HIV replication and the emergence of drug resistance on ART Virus Evolution. 5. DOI: 10.1093/Ve/Vez002.011 |
0.532 |
|
| 2019 |
Patro SC, Wu X, Guo S, Bale MJ, Wiegand A, Spindler J, Fennessey CM, Halvas EK, Keele BF, Hughes SH, Mellors JW, Coffin JM, Rausch JW, Kearney MF. A9 A method to obtain full-length HIV proviral sequences and their sites of integration Virus Evolution. 5. DOI: 10.1093/Ve/Vez002.008 |
0.465 |
|
| 2019 |
Riddler S, Para M, Benson C, Mills A, Ramgopal M, Dejesus E, Brinson C, Cyktor J, Mellors J, Guo S, Doehle B, Markova S, Patel H, Graham H, Hesselgesser J, et al. Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individuals Journal of Virus Eradication. 5: 3. DOI: 10.1016/S2055-6640(20)31079-7 |
0.553 |
|
| 2019 |
Cyktor J, Gandhi R, Bosch R, Mar H, Laird G, Macatangay B, Eron J, Siliciano R, Mcmahon D, Mellors J. Intact proviral DNA levels decline in people with HIV on antiretroviral therapy Journal of Virus Eradication. 5: 38. DOI: 10.1016/S2055-6640(20)30174-6 |
0.538 |
|
| 2019 |
Stevenson EM, Ward AR, Dilling TR, Bui JK, Mellors J, Gandhi R, McMahon D, Eron J, Bosch R, Lalama C, Cyktor J, Jones B. Dynamics of HIV-specific T cells on long-term ART differ by antigen recognised and by sex Journal of Virus Eradication. 5: 32. DOI: 10.1016/S2055-6640(20)30157-6 |
0.467 |
|
| 2019 |
Bale M, Katusiime MG, Wells D, Wu X, Coffin J, Cotton M, Hughes S, Mellors J, Zyl GV, Kearney M. Long-term persistence of HIV-infected cell clones in early treated children Journal of Virus Eradication. 5: 28. DOI: 10.1016/S2055-6640(20)30146-1 |
0.473 |
|
| 2019 |
Joseph K, Halvas E, Brandt L, Patro S, Rausch J, Kearney M, Coffin J, Mellors J. High-throughput sequencing of integrated HIV-1 reveals novel proviral structures Journal of Virus Eradication. 5: 25-26. DOI: 10.1016/S2055-6640(20)30138-2 |
0.521 |
|
| 2019 |
Jacobs J, Tosiano M, Koontz D, Worlock A, Harrington K, Shutt K, Bakkour S, Busch M, Mellors J. Automated high-throughput quantification of persistent HIV-1 plasma viremia in individuals on ART Journal of Virus Eradication. 5: 24-25. DOI: 10.1016/S2055-6640(20)30135-7 |
0.533 |
|
| 2019 |
Shao W, Shan J, Hu WS, Halvas E, Mellors J, Coffin J, Kearney M. Updates on two public databases for studies of HIV persistence; the Retrovirus Integration Database (RID) and HIV Proviral Sequence Database (PSD) Journal of Virus Eradication. 5: 12-13. DOI: 10.1016/S2055-6640(20)30103-5 |
0.565 |
|
| 2018 |
Rocco J, Mellors JW, Macatangay BJ. Regulatory T cells: the ultimate HIV reservoir? Journal of Virus Eradication. 4: 209-214. PMID 30515299 DOI: 10.1016/S2055-6640(20)30305-8 |
0.577 |
|
| 2018 |
Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, et al. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. The Lancet. Hiv. PMID 30503325 DOI: 10.1016/S2352-3018(18)30317-5 |
0.436 |
|
| 2018 |
Riddler SA, Zheng L, Durand CM, Ritz J, Koup RA, Ledgerwood J, Bailer RT, Koletar SL, Eron JJ, Keefer MC, Macatangay BJC, Cyktor JC, Mellors JW. Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART. Open Forum Infectious Diseases. 5: ofy242. PMID 30364428 DOI: 10.1093/Ofid/Ofy242 |
0.548 |
|
| 2018 |
Riddler SA, Balkus JE, Parikh UM, Mellors JW, Akello C, Dadabhai S, Mhlanga F, Ramjee G, Mayo AJ, Livant E, Heaps AL, O'Rourke C, Baeten JM. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the MTN-020/ASPIRE Phase III Trial of the Dapivirine Vaginal Ring. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30346511 DOI: 10.1093/Cid/Ciy909 |
0.581 |
|
| 2018 |
Margot N, Koontz D, McCallister S, Mellors JW, Callebaut C. Measurement of plasma HIV-1 RNA below the limit of quantification (<20 copies/mL) of commercial assays with the integrase HIV RNA single-copy assay. Journal of Clinical Virology : the Official Publication of the Pan American Society For Clinical Virology. 108: 50-52. PMID 30240941 DOI: 10.1016/j.jcv.2018.09.003 |
0.502 |
|
| 2018 |
Namazi G, Fajnzylber JM, Aga E, Bosch R, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, ... ... Mellors JW, et al. The Control of HIV after Antiretroviral Medication Pause (CHAMP) study: post-treatment controllers identified from 14 clinical studies. The Journal of Infectious Diseases. PMID 30085241 DOI: 10.1093/Infdis/Jiy479 |
0.52 |
|
| 2018 |
Hong F, Jacobs JL, Aga E, Cillo AR, Fyne E, Koontz DL, Zheng L, Mellors JW. Associations between HIV-1 DNA copy number, proviral transcriptional activity, and plasma viremia in individuals off or on suppressive antiretroviral therapy. Virology. 521: 51-57. PMID 29879542 DOI: 10.1016/J.Virol.2018.05.018 |
0.567 |
|
| 2018 |
Jennings C, Wager CG, Scianna SR, Zaccaro DJ, Couzens A, Mellors JW, Coombs RW, Bremer JW. Use of external quality control material for HIV-1 RNA testing to assess the comparability of data generated in separate laboratories and the stability of HIV-1 RNA in samples after prolonged storage. Journal of Clinical Microbiology. PMID 29618501 DOI: 10.1128/Jcm.00120-18 |
0.481 |
|
| 2018 |
Penrose KJ, Brumme CJ, Scoulos-Hanson M, Hamanishi K, Gordon K, Viana RV, Wallis CL, Harrigan PR, Mellors JW, Parikh UM. Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa. Antiviral Chemistry & Chemotherapy. 26: 2040206618762985. PMID 29566538 DOI: 10.1177/2040206618762985 |
0.643 |
|
| 2018 |
Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK, et al. Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. The Journal of Infectious Diseases. PMID 29529230 DOI: 10.1093/Infdis/Jiy011 |
0.585 |
|
| 2018 |
Kearney MF, Spindler J, Wiegand A, Shao W, Haubrich R, Riddler S, Lalama CM, Hughes MD, Coffin JM, Mellors JW. Lower pre-ART intra-participant HIV-1 pol diversity may not be associated with virologic failure in adults. Plos One. 13: e0190438. PMID 29370196 DOI: 10.1371/Journal.Pone.0190438 |
0.581 |
|
| 2018 |
Veldsman KA, Maritz J, Isaacs S, Katusiime MG, Janse Van Rensburg A, Laughton B, Mellors JW, Cotton MF, van Zyl GU. Rapid decline of HIV-1 DNA and RNA in infants starting very early ART may pose a diagnostic challenge. Aids (London, England). PMID 29334551 DOI: 10.1097/Qad.0000000000001739 |
0.561 |
|
| 2018 |
Cillo AR, Hong F, Tsai A, Irrinki A, Kaur J, Sloan DD, Follen M, Geleziunas R, Cihlar T, Win SS, Murry JP, Mellors JW. Blood biomarkers of expressed and inducible HIV-1. Aids (London, England). PMID 29334544 DOI: 10.1097/Qad.0000000000001748 |
0.517 |
|
| 2018 |
Nachega JB, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW. Achieving Viral Suppression in 90% of People Living with HIV on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29324994 DOI: 10.1093/Cid/Ciy008 |
0.415 |
|
| 2018 |
Veldkamp PJ, Mellors JW, Halvas EK. Should we be testing for baseline integrase resistance in patients newly diagnosed with human immunodeficiency virus? Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29324987 DOI: 10.1093/Cid/Ciy015 |
0.374 |
|
| 2018 |
Mellors J. D-103 HIV Cure Jaids Journal of Acquired Immune Deficiency Syndromes. 77: 39. DOI: 10.1097/01.Qai.0000532595.59554.19 |
0.541 |
|
| 2017 |
Kearney MF, Wiegand A, Shao W, McManus WR, Bale MJ, Luke B, Maldarelli F, Mellors JW, Coffin JM. Ongoing HIV Replication During ART Reconsidered. Open Forum Infectious Diseases. 4: ofx173. PMID 30310821 DOI: 10.1093/Ofid/Ofx173 |
0.534 |
|
| 2017 |
Park YJ, Etemad B, Ahmed H, Naranbhai V, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Carrington M, Li JZ. Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption. Pathogens & Immunity. 2: 431-445. PMID 29333522 DOI: 10.20411/pai.v2i3.222 |
0.487 |
|
| 2017 |
Wallis CL, Godfrey C, Fitzgibbon JE, Mellors JW. Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries. The Journal of Infectious Diseases. 216: S851-S856. PMID 29207000 DOI: 10.1093/Infdis/Jix409 |
0.514 |
|
| 2017 |
Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, et al. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. The Lancet. Hiv. PMID 29174084 DOI: 10.1016/S2352-3018(17)30190-X |
0.327 |
|
| 2017 |
Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, ... ... Mellors JW, et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. Plos Medicine. 14: e1002417. PMID 29112956 DOI: 10.1371/Journal.Pmed.1002417 |
0.58 |
|
| 2017 |
Thomas AS, Jones KL, Gandhi RT, McMahon DK, Cyktor JC, Chan D, Huang SH, Truong R, Bosque A, Macedo AB, Kovacs C, Benko E, Eron JJ, Bosch RJ, Lalama CM, ... ... Mellors JW, et al. mT-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. Plos Pathogens. 13: e1006629. PMID 28931091 DOI: 10.1371/Journal.Ppat.1006629 |
0.516 |
|
| 2017 |
Van Zyl GU, Katusiime MG, Wiegand A, McManus WR, Bale MJ, Halvas EK, Luke B, Boltz VF, Spindler J, Laughton B, Engelbrecht S, Coffin JM, Cotton MF, Shao W, Mellors JW, et al. No evidence of HIV replication in children on antiretroviral therapy. The Journal of Clinical Investigation. PMID 28891813 DOI: 10.1172/Jci94582 |
0.578 |
|
| 2017 |
Cardozo EF, Andrade A, Mellors JW, Kuritzkes DR, Perelson AS, Ribeiro RM. Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration. Plos Pathogens. 13: e1006478. PMID 28678879 DOI: 10.1371/Journal.Ppat.1006478 |
0.494 |
|
| 2017 |
Gay CL, Bosch RJ, Ritz J, Hataye JM, Aga E, Tressler RL, Mason SW, Hwang CK, Grasela DM, Ray N, Cyktor JC, Coffin JM, Acosta EP, Koup RA, Mellors JW, et al. Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy. The Journal of Infectious Diseases. PMID 28431010 DOI: 10.1093/Infdis/Jix191 |
0.491 |
|
| 2017 |
Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, Rinaldo CR, Riddler SA, Hogg E, Godfrey C, Collier AC, Eron JJ, Mellors JW. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. Plos Pathogens. 13: e1006285. PMID 28426825 DOI: 10.1371/Journal.Ppat.1006285 |
0.587 |
|
| 2017 |
Wiegand A, Spindler J, Hong FF, Shao W, Cyktor JC, Cillo AR, Halvas EK, Coffin JM, Mellors JW, Kearney MF. Single-cell analysis of HIV-1 transcriptional activity reveals expression of proviruses in expanded clones during ART. Proceedings of the National Academy of Sciences of the United States of America. PMID 28416661 DOI: 10.1073/Pnas.1617961114 |
0.577 |
|
| 2017 |
Cyktor JC, Mellors JW. TLR Agonists: Can They Exact a Toll on HIV Persistence? Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 28329288 DOI: 10.1093/Cid/Cix204 |
0.531 |
|
| 2017 |
Bui JK, Sobolewski MD, Keele BF, Spindler J, Musick A, Wiegand A, Luke BT, Shao W, Hughes SH, Coffin JM, Kearney MF, Mellors JW. Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir. Plos Pathogens. 13: e1006283. PMID 28328934 DOI: 10.1371/Journal.Ppat.1006283 |
0.608 |
|
| 2017 |
Bui JK, Halvas EK, Fyne E, Sobolewski MD, Koontz D, Shao W, Luke B, Hong FF, Kearney MF, Mellors JW. Ex vivo activation of CD4+ T-cells from donors on suppressive ART can lead to sustained production of infectious HIV-1 from a subset of infected cells. Plos Pathogens. 13: e1006230. PMID 28225830 DOI: 10.1371/Journal.Ppat.1006230 |
0.55 |
|
| 2017 |
Parikh UM, McCormick K, van Zyl G, Mellors JW. Future technologies for monitoring HIV drug resistance and cure. Current Opinion in Hiv and Aids. PMID 28059958 DOI: 10.1097/Coh.0000000000000344 |
0.613 |
|
| 2017 |
Ambinder RF, Wu J, Logan B, Durand C, Shields R, Popat UR, Little RF, Mcmahon D, Mellors JW, Ayala E, Kaplan LD, Noy A, Howard A, Forman SJ, Mendizabal AM, et al. Allogeneic hematopoietic cell transplant (alloHCT) for hematologic malignancies in human immunodeficiency virus infected (HIV) patients (pts): Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0903)/AIDS Malignancy Consortium (AMC-080) trial. Journal of Clinical Oncology. 35: 7006-7006. DOI: 10.1200/Jco.2017.35.15_Suppl.7006 |
0.466 |
|
| 2017 |
Mellors J. F-106 Clonally-amplified proviruses as reservoirs of HIV Jaids Journal of Acquired Immune Deficiency Syndromes. 74: 55. DOI: 10.1097/01.Qai.0000513854.94057.0F |
0.506 |
|
| 2017 |
Keating SM, Jones B, Lalama CM, Bosch R, McMahon D, Hampton D, Hogg E, Cyktor J, Eron JJ, Mellors JW, Busch MP, Gandhi RT. HIV antibody and T cell responses on ART are associated with HIV DNA but not RNA Journal of Virus Eradication. 3: 33. DOI: 10.1016/S2055-6640(20)30630-0 |
0.563 |
|
| 2017 |
Keating SM, Stone M, Deng X, Mellors J, Bakkour S, Richman D, Gorelick R, Lifson J, Jennings C, Stengelin M, Wu G, Howell BJ, Bacchetti P, Busch MP. Blinded evaluation of ultrasensitive assays of HIV in plasma Journal of Virus Eradication. 3: 24-25. DOI: 10.1016/S2055-6640(20)30625-7 |
0.528 |
|
| 2017 |
Stone M, Rosenbloom D, Bacchetti P, Deng X, Busch M, Dimapasoc M, Keating S, Richman D, Mellors J, Deeks S, Siliciano J, Chomont N, Ptak R. Next generation viral outgrowth assays as proxies for classic QVOA to measure HIV-1 reservoir size Journal of Virus Eradication. 3: 17. DOI: 10.1016/S2055-6640(20)30599-9 |
0.552 |
|
| 2017 |
McMahon D, Zheng L, Cyktor J, Aga E, Macatangay BJ, Godfrey C, Para M, Mitsuyasu R, Hogg E, Hesselgesser J, Acosta E, Gandhi RT, Mellors JW. Single romidepsin infusions do not increase HIV expression in persons on ART (A5315) Journal of Virus Eradication. 3: 41-42. DOI: 10.1016/S2055-6640(20)30557-4 |
0.489 |
|
| 2017 |
McManus WR, Bale MJ, Spindler J, Wiegand A, Musick A, Wu X, Wells D, Hughes SH, Keele BF, Hoh R, Mulish J, Coffin JM, Mellors JW, Deeks SG, Kearney MF. No evidence for ongoing HIV replication in lymph nodes during suppressive ART Journal of Virus Eradication. 3: 21. DOI: 10.1016/S2055-6640(20)30542-2 |
0.47 |
|
| 2017 |
McManus WR, Bale MJ, Musick A, Spindler J, Wiegand A, Wu X, Wells D, Hughes SH, Keele BF, Hoh R, Milush J, Coffin JM, Mellors JW, Deeks SG, Kearney MF. Characterizing HIV expression of proviruses during ART in tissues and blood Journal of Virus Eradication. 3: 20. DOI: 10.1016/S2055-6640(20)30539-2 |
0.506 |
|
| 2016 |
Boltz VF, Rausch J, Shao W, Hattori J, Luke B, Maldarelli F, Mellors JW, Kearney MF, Coffin JM. Ultrasensitive single-genome sequencing: accurate, targeted, next generation sequencing of HIV-1 RNA. Retrovirology. 13: 87. PMID 27998286 DOI: 10.1186/S12977-016-0321-6 |
0.447 |
|
| 2016 |
Wallis CL, Viana RV, Saravanan S, de Jesus CS, Zeh C, Halvas EK, Mellors JW. Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes. Journal of Virological Methods. PMID 27993614 DOI: 10.1016/J.Jviromet.2016.12.008 |
0.607 |
|
| 2016 |
Penrose KJ, Wallis CL, Brumme CJ, Hamanishi KA, Gordon KC, Viana RV, Harrigan PR, Mellors JW, Parikh UM. Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals on Failing First-Line Antiretroviral Therapy in South Africa. Antimicrobial Agents and Chemotherapy. PMID 27895013 DOI: 10.1128/Aac.01805-16 |
0.612 |
|
| 2016 |
Lewin SR, Mellors JW. HIV persistence in the CNS: the final frontier for a cure? Journal of Virus Eradication. 2: 242. PMID 27781108 |
0.51 |
|
| 2016 |
Glaubius RL, Parikh UM, Hood G, Penrose KJ, Bendavid E, Mellors JW, Abbas UL. Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention. Open Forum Infectious Diseases. 3: ofw125. PMID 27703992 DOI: 10.1093/Ofid/Ofw125 |
0.508 |
|
| 2016 |
Heffron R, Parikh UM, Penrose KJ, Mugo N, Donnell D, Celum C, Mellors JW, Baeten JM. Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception. Aids and Behavior. PMID 27699594 DOI: 10.1007/S10461-016-1563-Y |
0.393 |
|
| 2016 |
Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC. A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathogens & Immunity. 1: 154-164. PMID 27668293 DOI: 10.20411/pai.v1i1.133 |
0.505 |
|
| 2016 |
Policicchio BB, Xu C, Brocca-Cofano E, Raehtz KD, He T, Ma D, Li H, Sivanandham R, Haret-Richter GS, Dunsmore T, Trichel A, Mellors JW, Hahn BH, Shaw GM, Ribeiro RM, et al. Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. Plos Pathogens. 12: e1005879. PMID 27632364 DOI: 10.1371/Journal.Ppat.1005879 |
0.395 |
|
| 2016 |
Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, Chomont N, Douek D, Lifson JD, Lo YR, Kuritzkes D, Margolis D, Mellors J, Persaud D, Tucker JD, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine. PMID 27400264 DOI: 10.1038/Nm.4108 |
0.578 |
|
| 2016 |
Dimitrov DT, Boily MC, Hallett TB, Albert J, Boucher C, Mellors JW, Pillay D, van de Vijver DA. How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. Plos One. 11: e0158620. PMID 27391094 DOI: 10.1371/Journal.Pone.0158620 |
0.321 |
|
| 2016 |
Rutstein SE, Hosseinipour MC, Weinberger M, Wheeler SB, Biddle AK, Wallis CL, Balakrishnan P, Mellors JW, Morgado M, Saravanan S, Tripathy S, Vardhanabhuti S, Eron JJ, Miller WC. Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm. Bmc Infectious Diseases. 16: 280. PMID 27296625 DOI: 10.1186/S12879-016-1611-2 |
0.354 |
|
| 2016 |
La Rosa AM, Harrison LJ, Taiwo B, Wallis CL, Zheng L, Kim P, Kumarasamy N, Hosseinipour MC, Jarocki B, Mellors JW, Collier AC. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. The Lancet. Hiv. 3: e247-58. PMID 27240787 DOI: 10.1016/S2352-3018(16)30011-X |
0.365 |
|
| 2016 |
Glaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E, Abbas UL. Cost-Effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 27193745 DOI: 10.1093/Cid/Ciw321 |
0.51 |
|
| 2016 |
Cillo AR, Mellors JW. Which therapeutic strategy will achieve a cure for HIV-1? Current Opinion in Virology. 18: 14-19. PMID 26985878 DOI: 10.1016/J.Coviro.2016.02.001 |
0.591 |
|
| 2016 |
Treasure GC, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Li JZ. Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 26910502 DOI: 10.1097/Qai.0000000000000964 |
0.345 |
|
| 2016 |
Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, Mgodi NM, Matovu Kiweewa F, Nair G, Mhlanga F, Siva S, Bekker LG, Jeenarain N, Gaffoor Z, Martinson F, ... ... Mellors JW, et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. The New England Journal of Medicine. PMID 26900902 DOI: 10.1097/01.Ogx.0000489577.60775.40 |
0.549 |
|
| 2016 |
Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, Anderson EM, Watters SA, Hill S, Wu X, Wells D, Su L, Luke BT, Halvas EK, Besson G, ... ... Mellors JW, et al. Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. Proceedings of the National Academy of Sciences of the United States of America. PMID 26858442 DOI: 10.1073/Pnas.1522675113 |
0.519 |
|
| 2016 |
Hong F, Aga E, Cillo A, Yates AL, Besson G, Fyne E, Koontz DL, Jennings C, Zheng L, Mellors JW. Novel assays to measure total cell-associated HIV-1 DNA and RNA. Journal of Clinical Microbiology. PMID 26763968 DOI: 10.1128/Jcm.02904-15 |
0.556 |
|
| 2016 |
Parikh UM, Mellors JW. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? Current Opinion in Hiv and Aids. 11: 49-55. PMID 26633640 DOI: 10.1097/Coh.0000000000000209 |
0.593 |
|
| 2016 |
Maldarelli F, Wu X, Su L, Simonetti F, Wells D, Shao W, Spindler J, Ferris A, Mellors J, Kearney M, Coffin J, Hughes S. B-108 Specific HIV integration sites are linked to clonal expansion and persistence of infected cells Jaids Journal of Acquired Immune Deficiency Syndromes. 71: 44. DOI: 10.1097/01.Qai.0000479721.09749.2D |
0.498 |
|
| 2015 |
Macatangay BJ, Riddler SA, Wheeler ND, Spindler J, Lawani M, Hong F, Buffo MJ, Whiteside TL, Kearney MF, Mellors JW, Rinaldo CR. Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. The Journal of Infectious Diseases. PMID 26647281 DOI: 10.1093/Infdis/Jiv582 |
0.503 |
|
| 2015 |
Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. Aids (London, England). PMID 26588174 DOI: 10.1097/Qad.0000000000000953 |
0.533 |
|
| 2015 |
Kearney MF, Wiegand A, Shao W, Coffin JM, Mellors JW, Lederman M, Gandhi RT, Keele BF, Li JZ. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses that are Transcriptionally Active Before Stopping Antiretroviral Therapy. Journal of Virology. PMID 26581989 DOI: 10.1128/Jvi.02139-15 |
0.552 |
|
| 2015 |
Penrose K, Parikh UM, Hamanishi KA, Else L, Back D, Boffito M, Jackson A, Mellors JW. Selection of Rilpivirine Resistant HIV-1 in a Seroconverter on Long-Acting Rilpivirine (TMC278LA) from the Lowest Dose Arm of the SSAT040 Trial. The Journal of Infectious Diseases. PMID 26563240 DOI: 10.1093/Infdis/Jiv528 |
0.638 |
|
| 2015 |
Bui JK, Mellors JW, Cillo AR. HIV-1 Virion Production from Single Inducible Proviruses following T-Cell Activation Ex Vivo. Journal of Virology. 90: 1673-6. PMID 26559835 DOI: 10.1128/Jvi.02520-15 |
0.542 |
|
| 2015 |
Kearney MF, Anderson EM, Coomer C, Smith L, Shao W, Johnson N, Kline C, Spindler J, Mellors JW, Coffin JM, Ambrose Z. Well-mixed plasma and tissue viral populations in RT-SHIV-infected macaques implies a lack of viral replication in the tissues during antiretroviral therapy. Retrovirology. 12: 93. PMID 26559632 DOI: 10.1186/S12977-015-0212-2 |
0.394 |
|
| 2015 |
Andrade A, Guedj J, Rosenkranz SL, Lu D, Mellors J, Kuritzkes DR, Perelson AS, Ribeiro RM. Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). Aids (London, England). 29: 2419-26. PMID 26558541 DOI: 10.1097/Qad.0000000000000843 |
0.539 |
|
| 2015 |
Cillo AR, Hilldorfer BB, Lalama CM, McKinnon JE, Coombs RW, Tenorio AR, Fox L, Gandhi RT, Ribaudo H, Currier JS, Gulick RM, Wilkin TJ, Mellors JW. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. Aids (London, England). 29: 2121-9. PMID 26544577 DOI: 10.1097/Qad.0000000000000810 |
0.483 |
|
| 2015 |
Melody K, McBeth S, Kline C, Kashuba AD, Mellors JW, Ambrose Z. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase. Antimicrobial Agents and Chemotherapy. 59: 7762-70. PMID 26438501 DOI: 10.1128/Aac.01937-15 |
0.569 |
|
| 2015 |
Ananworanich J, Mellors JW. How Much HIV is Alive? The Challenge of Measuring Replication Competent HIV for HIV Cure Research. Ebiomedicine. 2: 786-7. PMID 26425677 DOI: 10.1016/J.Ebiom.2015.07.036 |
0.616 |
|
| 2015 |
Ouyang Z, Buzon MJ, Zheng L, Sun H, Yu XG, Bosch RJ, Mellors JW, Eron JJ, Gandhi RT, Lichterfeld M. Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir. Open Forum Infectious Diseases. 2: ofv045. PMID 26380343 DOI: 10.1093/Ofid/Ofv045 |
0.478 |
|
| 2015 |
Bui JK, Mellors JW. Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1. Aids (London, England). 29: 1911-5. PMID 26355569 DOI: 10.1097/Qad.0000000000000788 |
0.318 |
|
| 2015 |
Riddler SA, Aga E, Bosch RJ, Bastow B, Bedison M, Vagratian D, Vaida F, Eron JJ, Gandhi RT, Mellors JW. Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. The Journal of Infectious Diseases. PMID 26333941 DOI: 10.1093/Infdis/Jiv433 |
0.543 |
|
| 2015 |
Lalama CM, Jennings C, Johnson VA, Coombs RW, McKinnon JE, Bremer JW, Cobb BR, Cloherty GA, Mellors JW, Ribaudo HJ. Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity. Journal of Clinical Microbiology. 53: 2659-66. PMID 26063861 DOI: 10.1128/Jcm.00801-15 |
0.545 |
|
| 2015 |
Hong FF, Mellors JW. Impact of Antiretroviral Therapy on HIV-1 Persistence: The Case for Early Initiation. Aids Reviews. 17: 71-82. PMID 26035165 |
0.449 |
|
| 2015 |
Hong FF, Mellors JW. Impact of Antiretroviral Therapy on HIV-1 Persistence: The Case for Early Initiation. Aids Reviews. 17. PMID 25946416 |
0.454 |
|
| 2015 |
Li JZ, Smith DM, Mellors JW. The critical roles of treatment interruption studies and biomarker identification in the search for an HIV cure. Aids (London, England). PMID 25870989 DOI: 10.1097/Qad.0000000000000658 |
0.605 |
|
| 2015 |
Ma D, Xu C, Cillo AR, Policicchio B, Kristoff J, Haret-Richter G, Mellors JW, Pandrea I, Apetrei C. Simian Immunodeficiency Virus SIVsab Infection of Rhesus Macaques as a Model of Complete Immunological Suppression with Persistent Reservoirs of Replication-Competent Virus: Implications for Cure Research. Journal of Virology. 89: 6155-60. PMID 25833043 DOI: 10.1128/Jvi.00256-15 |
0.358 |
|
| 2015 |
Luzuriaga K, Gay H, Ziemniak C, Sanborn KB, Somasundaran M, Rainwater-Lovett K, Mellors JW, Rosenbloom D, Persaud D. Viremic relapse after HIV-1 remission in a perinatally infected child. The New England Journal of Medicine. 372: 786-8. PMID 25693029 DOI: 10.1056/Nejmc1413931 |
0.574 |
|
| 2015 |
Kantor R, Smeaton L, Vardhanabhuti S, Hudelson SE, Wallis CL, Tripathy S, Morgado MG, Saravanan S, Balakrishnan P, Reitsma M, Hart S, Mellors JW, Halvas E, Grinsztejn B, Hosseinipour MC, et al. Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 60: 1541-9. PMID 25681380 DOI: 10.1093/Cid/Civ102 |
0.554 |
|
| 2015 |
van Zyl GU, Bedison MA, van Rensburg AJ, Laughton B, Cotton MF, Mellors JW. Early Antiretroviral Therapy in South African Children Reduces HIV-1-Infected Cells and Cell-Associated HIV-1 RNA in Blood Mononuclear Cells. The Journal of Infectious Diseases. 212: 39-43. PMID 25538273 DOI: 10.1093/Infdis/Jiu827 |
0.574 |
|
| 2015 |
Hong FF, Mellors JW. Changes in HIV reservoirs during long-term antiretroviral therapy. Current Opinion in Hiv and Aids. 10: 43-8. PMID 25402706 DOI: 10.1097/Coh.0000000000000119 |
0.523 |
|
| 2015 |
Ananworanich J, Mellors JW. A cure for HIV: what will it take? Current Opinion in Hiv and Aids. 10: 1-3. PMID 25389807 DOI: 10.1097/Coh.0000000000000125 |
0.597 |
|
| 2015 |
Macatangay B, Blain CK, Hong F, Bui J, Cillo A, Mellors J. Co-expression of multiple inhibitory receptors on CD8 + T cells in viremic and ART-suppressed HIV-1(+) individuals Journal of Virus Eradication. 1: 36. DOI: 10.1016/S2055-6640(20)31400-X |
0.469 |
|
| 2015 |
Hong FF, Michael H, Qin S, Kingsley LA, McMahon DD, Fitzpatrick ME, Morris AM, Mellors JW. Persistence of HIV-infected alveolar macrophages after suppressive ART Journal of Virus Eradication. 1: 8. DOI: 10.1016/S2055-6640(20)31308-X |
0.547 |
|
| 2015 |
Kearney MF, Spindler J, Sobolewski M, Coffin JM, Mellors JW. In vivo expression of unspliced HIV RNA in expanded CD4 + T-cell clones containing defective or replication-competent proviruses Journal of Virus Eradication. 1: 6. DOI: 10.1016/S2055-6640(20)31302-9 |
0.483 |
|
| 2015 |
Cillo A, Hong F, Tsai A, Irrinki A, Kaur J, Lalezari J, Sloan D, Murry JP, Mellors J. Cellular HIV RNA/DNA as biomarkers of inducible virion production Journal of Virus Eradication. 1: 3. DOI: 10.1016/S2055-6640(20)31292-9 |
0.491 |
|
| 2014 |
Hitti J, Halvas EK, Zheng L, Panousis CG, Kabanda J, Taulo F, Kumarasamy N, Pape JW, Lalloo U, Sprenger H, Klingman KL, Chan ES, McMahon D, Mellors JW. Frequency of Antiretroviral Resistance Mutations among Infants Exposed to Single-Dose Nevirapine and Short Course Maternal Antiretroviral Regimens: ACTG A5207. Journal of Aids & Clinical Research. 5. PMID 26525108 DOI: 10.4172/2155-6113.1000371 |
0.47 |
|
| 2014 |
van Zyl GU, Frenkel LM, Chung MH, Preiser W, Mellors JW, Nachega JB. Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits. Aids (London, England). 28: 2643-8. PMID 25493592 DOI: 10.1097/Qad.0000000000000502 |
0.463 |
|
| 2014 |
Penrose KJ, Richardson BA, Besson G, Dezzutti CS, Herold BC, Abdool Karim SS, Mellors JW, Parikh UM. Y chromosome and HIV DNA detection in vaginal swabs as biomarkers of semen and HIV exposure in women. Sexually Transmitted Diseases. 41: 674-9. PMID 25299415 DOI: 10.1097/Olq.0000000000000191 |
0.543 |
|
| 2014 |
Cillo AR, Vagratian D, Bedison MA, Anderson EM, Kearney MF, Fyne E, Koontz D, Coffin JM, Piatak M, Mellors JW. Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. Journal of Clinical Microbiology. 52: 3944-51. PMID 25187636 DOI: 10.1128/Jcm.02060-14 |
0.518 |
|
| 2014 |
Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, Riddler SA, McMahon DK, Hong F, Mellors JW. HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 59: 1312-21. PMID 25073894 DOI: 10.1093/Cid/Ciu585 |
0.544 |
|
| 2014 |
Bhardwaj N, Maldarelli F, Mellors J, Coffin JM. HIV-1 infection leads to increased transcription of human endogenous retrovirus HERV-K (HML-2) proviruses in vivo but not to increased virion production. Journal of Virology. 88: 11108-20. PMID 25056891 DOI: 10.1128/Jvi.01623-14 |
0.517 |
|
| 2014 |
Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, Spindler J, Ferris AL, Mellors JW, Kearney MF, Coffin JM, Hughes SH. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science (New York, N.Y.). 345: 179-83. PMID 24968937 DOI: 10.1126/Science.1254194 |
0.563 |
|
| 2014 |
McKinnon JE, Mailliard RB, Swindells S, Wilkin TJ, Borowski L, Roper JM, Bastow B, Kearney M, Wiegand A, Mellors JW, Rinaldo CR. Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201). Plos One. 9: e95524. PMID 24802242 DOI: 10.1371/Journal.Pone.0095524 |
0.436 |
|
| 2014 |
Sluis-Cremer N, Jordan MR, Huber K, Wallis CL, Bertagnolio S, Mellors JW, Parkin NT, Harrigan PR. E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings. Antiviral Research. 107: 31-4. PMID 24746459 DOI: 10.1016/J.Antiviral.2014.04.001 |
0.539 |
|
| 2014 |
Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, ... ... Mellors J, et al. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. Plos Pathogens. 10: e1004071. PMID 24722454 DOI: 10.1371/Journal.Ppat.1004071 |
0.605 |
|
| 2014 |
Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M, Coffin JM, Mellors JW. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America. 111: 7078-83. PMID 24706775 DOI: 10.1073/Pnas.1402873111 |
0.498 |
|
| 2014 |
Kearney MF, Spindler J, Shao W, Yu S, Anderson EM, O'Shea A, Rehm C, Poethke C, Kovacs N, Mellors JW, Coffin JM, Maldarelli F. Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. Plos Pathogens. 10: e1004010. PMID 24651464 DOI: 10.1371/Journal.Ppat.1004010 |
0.524 |
|
| 2014 |
Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW. Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy. Plos One. 9: e92118. PMID 24638072 DOI: 10.1371/Journal.Pone.0092118 |
0.61 |
|
| 2014 |
Doyon G, Sobolewski MD, Huber K, McMahon D, Mellors JW, Sluis-Cremer N. Discovery of a small molecule agonist of phosphatidylinositol 3-kinase p110α that reactivates latent HIV-1. Plos One. 9: e84964. PMID 24489654 DOI: 10.1371/Journal.Pone.0084964 |
0.607 |
|
| 2014 |
Boltz VF, Bao Y, Lockman S, Halvas EK, Kearney MF, McIntyre JA, Schooley RT, Hughes MD, Coffin JM, Mellors JW. Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP. The Journal of Infectious Diseases. 209: 703-10. PMID 24443547 DOI: 10.1093/Infdis/Jit635 |
0.406 |
|
| 2014 |
Meteer JD, Schinazi RF, Mellors JW, Sluis-Cremer N. Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine. Antiviral Research. 101: 62-7. PMID 24211331 DOI: 10.1016/J.Antiviral.2013.10.017 |
0.841 |
|
| 2014 |
Abbas UL, Glaubius R, Hood G, Mellors JW. Antiretroviral treatment, preexposure prophylaxis, and drug resistance in sub-Saharan Africa: a consensus among mathematical models. The Journal of Infectious Diseases. 209: 164-6. PMID 24133186 DOI: 10.1093/Infdis/Jit545 |
0.343 |
|
| 2014 |
Mellors J. B-101 Prospects and Strategies for an HIV Cure Jaids Journal of Acquired Immune Deficiency Syndromes. 67: 43. DOI: 10.1097/01.Qai.0000456067.68309.55 |
0.543 |
|
| 2014 |
Li J, Aga E, Bosch R, Mellors J, Kuritzkes D, Para M, Gandhi R. 541HIV Rebound Kinetics and CD4+ T-Cell Loss after Treatment Interruption: A Pooled Analysis of Six AIDS Clinical Trials Group (ACTG) Studies Open Forum Infectious Diseases. 1: S23-S23. DOI: 10.1093/Ofid/Ofu051.60 |
0.47 |
|
| 2014 |
Maritz J, van Zyl G, Mellors J, Theron G, Nachega J, Rabie H, Holgate S, Preiser W, Bester M, Cotton M. Feasibility of a targeted, very early infant HIV diagnosis algorithm in a resource-limited setting International Journal of Infectious Diseases. 21: 129. DOI: 10.1016/J.Ijid.2014.03.695 |
0.402 |
|
| 2013 |
Kline C, Ndjomou J, Franks T, Kiser R, Coalter V, Smedley J, Piatak M, Mellors JW, Lifson JD, Ambrose Z. Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model. Plos One. 8: e84275. PMID 24367650 DOI: 10.1371/Journal.Pone.0084275 |
0.507 |
|
| 2013 |
Funderburg NT, Andrade A, Chan ES, Rosenkranz SL, Lu D, Clagett B, Pilch-Cooper HA, Rodriguez B, Feinberg J, Daar E, Mellors J, Kuritzkes D, Jacobson JM, Lederman MM. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. Plos One. 8: e83514. PMID 24367599 DOI: 10.1371/Journal.Pone.0083514 |
0.514 |
|
| 2013 |
Schuler PJ, Macatangay BJ, Saze Z, Jackson EK, Riddler SA, Buchanan WG, Hilldorfer BB, Mellors JW, Whiteside TL, Rinaldo CR. CD4⁺CD73⁺ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIV-1 infection regardless of viral suppression. Aids (London, England). 27: 1545-55. PMID 24005375 DOI: 10.1097/Qad.0B013E328360C7F3 |
0.472 |
|
| 2013 |
van de Vijver DA, Nichols BE, Abbas UL, Boucher CA, Cambiano V, Eaton JW, Glaubius R, Lythgoe K, Mellors J, Phillips A, Sigaloff KC, Hallett TB. Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. Aids (London, England). 27: 2943-51. PMID 23939237 DOI: 10.1097/01.Aids.0000433237.63560.20 |
0.584 |
|
| 2013 |
Josefsson L, Palmer S, Faria NR, Lemey P, Casazza J, Ambrozak D, Kearney M, Shao W, Kottilil S, Sneller M, Mellors J, Coffin JM, Maldarelli F. Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. Plos Pathogens. 9: e1003432. PMID 23818847 DOI: 10.1371/Journal.Ppat.1003432 |
0.566 |
|
| 2013 |
Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. The Journal of Infectious Diseases. 208: 884-91. PMID 23801609 DOI: 10.1093/Infdis/Jit272 |
0.491 |
|
| 2013 |
Maldarelli F, Kearney M, Palmer S, Stephens R, Mican J, Polis MA, Davey RT, Kovacs J, Shao W, Rock-Kress D, Metcalf JA, Rehm C, Greer SE, Lucey DL, Danley K, ... ... Mellors JW, et al. HIV populations are large and accumulate high genetic diversity in a nonlinear fashion. Journal of Virology. 87: 10313-23. PMID 23678164 DOI: 10.1128/Jvi.01225-12 |
0.509 |
|
| 2013 |
Parikh UM, Kiepiela P, Ganesh S, Gomez K, Horn S, Eskay K, Kelly C, Mensch B, Gorbach P, Soto-Torres L, Ramjee G, Mellors JW. Prevalence of HIV-1 drug resistance among women screening for HIV prevention trials in KwaZulu-Natal, South Africa (MTN-009). Plos One. 8: e59787. PMID 23585827 DOI: 10.1371/Journal.Pone.0059787 |
0.629 |
|
| 2013 |
Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW. Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. The Journal of Infectious Diseases. 208: 224-34. PMID 23570850 DOI: 10.1093/Infdis/Jit150 |
0.581 |
|
| 2013 |
Cillo AR, Krishnan A, Mitsuyasu RT, McMahon DK, Li S, Rossi JJ, Zaia JA, Mellors JW. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. Journal of Acquired Immune Deficiency Syndromes (1999). 63: 438-41. PMID 23493152 DOI: 10.1097/Qai.0B013E31828E6163 |
0.55 |
|
| 2013 |
Gandhi RT, Bosch RJ, Aga E, Bedison MA, Bastow B, Schmitz JL, Siliciano JD, Siliciano RF, Eron JJ, Mellors JW. Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173. Antiviral Therapy. 18: 607-13. PMID 23411421 DOI: 10.3851/Imp2543 |
0.529 |
|
| 2013 |
Shao W, Boltz VF, Spindler JE, Kearney MF, Maldarelli F, Mellors JW, Stewart C, Volfovsky N, Levitsky A, Stephens RM, Coffin JM. Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology. 10: 18. PMID 23402264 DOI: 10.1186/1742-4690-10-18 |
0.555 |
|
| 2013 |
McMahon DK, Zheng L, Hitti J, Chan ES, Halvas EK, Hong F, Kabanda J, Taulo F, Kumarasamy N, Bonhomme J, Wallis CL, Klingman KL, Hughes MD, Mellors JW. Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 56: 1044-51. PMID 23300238 DOI: 10.1093/Cid/Cis1219 |
0.541 |
|
| 2013 |
Zheng L, Bosch RJ, Chan ES, Read S, Kearney M, Margolis DM, Mellors JW, Eron JJ, Gandhi RT. Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antiviral Therapy. 18: 39-43. PMID 22914318 DOI: 10.3851/Imp2323 |
0.465 |
|
| 2013 |
Doyon G, Zerbato J, Mellors JW, Sluis-Cremer N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. Aids (London, England). 27: F7-F11. PMID 22739395 DOI: 10.1097/Qad.0B013E3283570620 |
0.582 |
|
| 2012 |
Apetrei C, Pandrea I, Mellors JW. Nonhuman primate models for HIV cure research. Plos Pathogens. 8: e1002892. PMID 22956905 DOI: 10.1371/Journal.Ppat.1002892 |
0.567 |
|
| 2012 |
Boltz VF, Ambrose Z, Kearney MF, Shao W, Kewalramani VN, Maldarelli F, Mellors JW, Coffin JM. Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase. Journal of Virology. 86: 12525-30. PMID 22933296 DOI: 10.1128/Jvi.01963-12 |
0.516 |
|
| 2012 |
Parikh UM, Mellors JW. Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens. Future Microbiology. 7: 929-32. PMID 22913352 DOI: 10.2217/Fmb.12.72 |
0.462 |
|
| 2012 |
Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M, Katlama C, Lafeuillade A, Landay A, Lederman M, Lewin SR, ... ... Mellors J, et al. Towards an HIV cure: a global scientific strategy. Nature Reviews. Immunology. 12: 607-14. PMID 22814509 DOI: 10.1038/Nri3262 |
0.574 |
|
| 2012 |
Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR. A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⺠T-cell recovery despite sustained virologic suppression: ACTG A5256. The Journal of Infectious Diseases. 206: 534-42. PMID 22740718 DOI: 10.1093/Infdis/Jis376 |
0.499 |
|
| 2012 |
Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, ... ... Mellors J, et al. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. Plos Medicine. 9: e1001236. PMID 22719231 DOI: 10.1371/Journal.Pmed.1001236 |
0.533 |
|
| 2012 |
Brehm JH, Koontz DL, Wallis CL, Shutt KA, Sanne I, Wood R, McIntyre JA, Stevens WS, Sluis-Cremer N, Mellors JW. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 737-45. PMID 22618567 DOI: 10.1093/Cid/Cis501 |
0.835 |
|
| 2012 |
Parikh UM, Mellors JW. HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 55: 303-4; author reply . PMID 22491333 DOI: 10.1093/Cid/Cis373 |
0.612 |
|
| 2012 |
Brehm JH, Scott Y, Koontz DL, Perry S, Hammer S, Katzenstein D, Mellors JW, Sluis-Cremer N. Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. Plos One. 7: e31558. PMID 22363673 DOI: 10.1371/Journal.Pone.0031558 |
0.859 |
|
| 2012 |
Palmer S, Boltz VF, Chow JY, Martinson NA, McIntyre JA, Gray GE, Hopley MJ, Mayers D, Robinson P, Hall DB, Maldarelli F, Coffin JM, Mellors JW. Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Antiviral Therapy. 17: 327-36. PMID 22293443 DOI: 10.3851/Imp1946 |
0.342 |
|
| 2012 |
Hilldorfer BB, Cillo AR, Besson GJ, Bedison MA, Mellors JW. New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. Current Hiv/Aids Reports. 9: 91-100. PMID 22215419 DOI: 10.1007/S11904-011-0104-6 |
0.597 |
|
| 2012 |
Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, ... Mellors JW, et al. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes (1999). 59: 229-35. PMID 22083073 DOI: 10.1097/Qai.0B013E31823Fd1F2 |
0.59 |
|
| 2012 |
Besson GJ, McMahon D, Maldarelli F, Mellors JW. Short-course raltegravir intensification does not increase 2 long terminal repeat episomal HIV-1 DNA in patients on effective antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 54: 451-3. PMID 22016501 DOI: 10.1093/Cid/Cir721 |
0.61 |
|
| 2012 |
Herman BD, Schinazi RF, Zhang HW, Nettles JH, Stanton R, Detorio M, Obikhod A, Pradère U, Coats SJ, Mellors JW, Sluis-Cremer N. Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3'-azido-2',3'-dideoxyguanosine-5'-triphosphates as adenosine analogs. Nucleic Acids Research. 40: 381-90. PMID 21914723 DOI: 10.1093/Nar/Gkr756 |
0.498 |
|
| 2012 |
Conradie F, Zheng Y, Hosseinipour M, Mellors J, Sawe F, Eshleman S, Mohapi L, Chipato T, Asmelash A, Stringer E, Siika A, Rwambuya S, Ramnarain P, Hogg E, Blanchard-Horan C, et al. Approaches to effectively documenting prior single dose nevirapine exposure among women in Africa Annals of Tropical Medicine and Public Health. 5: 344-348. DOI: 10.4103/1755-6783.102051 |
0.364 |
|
| 2011 |
Spindler J, Hackett J, Qiu X, Wiegand A, Boltz VF, Swanson P, Bream JH, Jacobson LP, Li X, Rinaldo CR, Wolinsky SM, Coffin JM, Kearney MF, Mellors JW. Prevalence of XMRV nucleic acid and antibody in HIV-1-Infected men and in men at risk for HIV-1 Infection. Advances in Virology. 2011: 268214. PMID 22282703 DOI: 10.1155/2011/268214 |
0.479 |
|
| 2011 |
Mens H, Kearney M, Wiegand A, Spindler J, Maldarelli F, Mellors JW, Coffin JM. Amplifying and quantifying HIV-1 RNA in HIV infected individuals with viral loads below the limit of detection by standard clinical assays. Journal of Visualized Experiments : Jove. PMID 21968801 DOI: 10.3791/2960 |
0.512 |
|
| 2011 |
Haubrich RH, Riddler SA, Ribaudo H, Direnzo G, Klingman KL, Garren KW, Butcher DL, Rooney JF, Havlir DV, Mellors JW. Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. Aids (London, England). 25: 2269-78. PMID 21941167 DOI: 10.1097/Qad.0B013E32834D0C20 |
0.58 |
|
| 2011 |
Dezzutti CS, Hendrix CW, Marrazzo JM, Pan Z, Wang L, Louissaint N, Kalyoussef S, Torres NM, Hladik F, Parikh U, Mellors J, Hillier SL, Herold BC. Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. Plos One. 6: e23136. PMID 21858008 DOI: 10.1371/Journal.Pone.0023136 |
0.377 |
|
| 2011 |
McKinnon JE, Delgado R, Pulido F, Shao W, Arribas JR, Mellors JW. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. Antiviral Therapy. 16: 725-32. PMID 21817194 DOI: 10.3851/Imp1812 |
0.586 |
|
| 2011 |
Zhang HW, Detorio M, Herman BD, Solomon S, Bassit L, Nettles JH, Obikhod A, Tao SJ, Mellors JW, Sluis-Cremer N, Coats SJ, Schinazi RF. Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides. European Journal of Medicinal Chemistry. 46: 3832-44. PMID 21700368 DOI: 10.1016/J.Ejmech.2011.05.051 |
0.483 |
|
| 2011 |
Josefsson L, King MS, Makitalo B, Brännström J, Shao W, Maldarelli F, Kearney MF, Hu WS, Chen J, Gaines H, Mellors JW, Albert J, Coffin JM, Palmer SE. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proceedings of the National Academy of Sciences of the United States of America. 108: 11199-204. PMID 21690402 DOI: 10.1073/Pnas.1107729108 |
0.554 |
|
| 2011 |
Meteer JD, Koontz D, Asif G, Zhang HW, Detorio M, Solomon S, Coats SJ, Sluis-Cremer N, Schinazi RF, Mellors JW. The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 55: 3758-64. PMID 21646480 DOI: 10.1128/Aac.00414-11 |
0.853 |
|
| 2011 |
Boltz VF, Zheng Y, Lockman S, Hong F, Halvas EK, McIntyre J, Currier JS, Chibowa MC, Kanyama C, Nair A, Owino-Ong'or W, Hughes M, Coffin JM, Mellors JW. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proceedings of the National Academy of Sciences of the United States of America. 108: 9202-7. PMID 21576473 DOI: 10.1073/Pnas.1105688108 |
0.398 |
|
| 2011 |
Huber K, Doyon G, Plaks J, Fyne E, Mellors JW, Sluis-Cremer N. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. The Journal of Biological Chemistry. 286: 22211-8. PMID 21531716 DOI: 10.1074/Jbc.M110.180224 |
0.59 |
|
| 2011 |
Abbas UL, Hood G, Wetzel AW, Mellors JW. Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP). Plos One. 6: e18165. PMID 21525976 DOI: 10.1371/Journal.Pone.0018165 |
0.562 |
|
| 2011 |
Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. Aids Research and Treatment. 2011: 769627. PMID 21490784 DOI: 10.1155/2011/769627 |
0.621 |
|
| 2011 |
Mascolini M, Mellors JW, Richman DD, Boucher CA, Larder BA. HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and curative strategies. Antiviral Therapy. 16: 263-86. PMID 21447877 DOI: 10.3851/Imp1761 |
0.606 |
|
| 2011 |
Brehm JH, Lalama CM, Hughes MD, Haubrich R, Riddler SA, Sluis-Cremer N, Mellors JW. Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. Journal of Acquired Immune Deficiency Syndromes (1999). 56: 344-8. PMID 21350368 DOI: 10.1097/Qai.0B013E31820Cf029 |
0.827 |
|
| 2011 |
Kearney M, Spindler J, Shao W, Maldarelli F, Palmer S, Hu SL, Lifson JD, KewalRamani VN, Mellors JW, Coffin JM, Ambrose Z. Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. Journal of Virology. 85: 1067-76. PMID 21084490 DOI: 10.1128/Jvi.01701-10 |
0.565 |
|
| 2011 |
Mellors JW. Community corner: The ART of preventing HIV Nature Medicine. 17: 46-47. DOI: 10.1038/nm0111-46 |
0.432 |
|
| 2010 |
Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. Hiv Clinical Trials. 11: 312-24. PMID 21239359 DOI: 10.1310/Hct1105-312 |
0.467 |
|
| 2010 |
Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, ... ... Mellors JW, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. The New England Journal of Medicine. 363: 1499-509. PMID 20942666 DOI: 10.1056/Nejmoa0906626 |
0.49 |
|
| 2010 |
Mens H, Kearney M, Wiegand A, Shao W, Schønning K, Gerstoft J, Obel N, Maldarelli F, Mellors JW, Benfield T, Coffin JM. HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. Journal of Virology. 84: 12971-81. PMID 20926564 DOI: 10.1128/Jvi.00387-10 |
0.622 |
|
| 2010 |
Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, Kallungal B, Palmer S, Medvik K, Lederman MM, Alatrakchi N, Jacobson JM, Wiegand A, Kearney M, Coffin JM, ... Mellors JW, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. Plos Medicine. 7. PMID 20711481 DOI: 10.1371/Journal.Pmed.1000321 |
0.576 |
|
| 2010 |
Kim SC, Becker S, Dieffenbach C, Hanewall BS, Hankins C, Lo YR, Mellors JW, O'Reilly K, Paxton L, Roffenbender JS, Warren M, Piot P, Dybul MR. Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities. Journal of the International Aids Society. 13: 24. PMID 20624303 DOI: 10.1186/1758-2652-13-24 |
0.506 |
|
| 2010 |
Barnas D, Koontz D, Bazmi H, Bixby C, Jemsek J, Mellors JW. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir. Antiviral Therapy. 15: 437-41. PMID 20516563 DOI: 10.3851/Imp1539 |
0.556 |
|
| 2010 |
Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, Jones L, Alston-Smith B, Rooney JF, Aberg JA. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. Aids (London, England). 24: 1781-4. PMID 20495438 DOI: 10.1097/Qad.0B013E32833Ad8B4 |
0.369 |
|
| 2010 |
McMahon D, Jones J, Wiegand A, Gange SJ, Kearney M, Palmer S, McNulty S, Metcalf JA, Acosta E, Rehm C, Coffin JM, Mellors JW, Maldarelli F. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 50: 912-9. PMID 20156060 DOI: 10.1086/650749 |
0.587 |
|
| 2010 |
Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, Wantman M, Hammer SM, Palmer S, Vaida F, Coffin JM, Mellors JW. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. The Journal of Infectious Diseases. 201: 672-80. PMID 20102272 DOI: 10.1086/650542 |
0.498 |
|
| 2010 |
Zhang HW, Coats SJ, Bondada L, Amblard F, Detorio M, Asif G, Fromentin E, Solomon S, Obikhod A, Whitaker T, Sluis-Cremer N, Mellors JW, Schinazi RF. Synthesis and evaluation of 3'-azido-2',3'-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus. Bioorganic & Medicinal Chemistry Letters. 20: 60-4. PMID 19948402 DOI: 10.1016/J.Bmcl.2009.11.031 |
0.505 |
|
| 2010 |
Boltz VF, Maldarelli F, Martinson N, Morris L, McIntyre JA, Gray G, Hopley MJ, Kimura T, Mayers DL, Robinson P, Mellors JW, Coffin JM, Palmer SE. Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design. Journal of Virological Methods. 164: 122-6. PMID 19948190 DOI: 10.1016/J.Jviromet.2009.11.025 |
0.491 |
|
| 2010 |
Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999). 53: 480-4. PMID 19801944 DOI: 10.1097/Qai.0B013E3181Bc478B |
0.575 |
|
| 2009 |
Mascolini M, Boucher CA, Mellors JW, Larder BA, Richman DD. Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop. Antiviral Therapy. 14: 1015-37. PMID 19918107 DOI: 10.3851/Imp1423 |
0.647 |
|
| 2009 |
Shao W, Kearney M, Maldarelli F, Mellors JW, Stephens RM, Lifson JD, KewalRamani VN, Ambrose Z, Coffin JM, Palmer SE. RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy. Retrovirology. 6: 101. PMID 19889213 DOI: 10.1186/1742-4690-6-101 |
0.554 |
|
| 2009 |
Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago BI, Detorio M, Rapp KL, Amblard F, Bondada L, Grier J, Coats SJ, Schinazi RF, Mellors JW. Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. Antimicrobial Agents and Chemotherapy. 53: 3715-9. PMID 19596885 DOI: 10.1128/Aac.00392-09 |
0.581 |
|
| 2009 |
Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, O'Shea A, Callender M, Spivak A, Brennan T, Kearney MF, Proschan MA, Mican JM, Rehm CA, Coffin JM, ... Mellors JW, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America. 106: 9403-8. PMID 19470482 DOI: 10.1073/Pnas.0903107106 |
0.61 |
|
| 2009 |
Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. Aids (London, England). 23: 1109-18. PMID 19417580 DOI: 10.1097/Qad.0B013E32832B4377 |
0.546 |
|
| 2009 |
McKinnon JE, Mellors JW, Swindells S. Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antiviral Therapy. 14: 1-12. PMID 19320232 |
0.414 |
|
| 2009 |
Wilkin TJ, McKinnon JE, DiRienzo AG, Mollan K, Fletcher CV, Margolis DM, Bastow B, Thal G, Woodward W, Godfrey C, Wiegand A, Maldarelli F, Palmer S, Coffin JM, Mellors JW, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. The Journal of Infectious Diseases. 199: 866-71. PMID 19191590 DOI: 10.1086/597119 |
0.326 |
|
| 2009 |
Mellors JW, Chow JY. Single-dose nevirapine to prevent mother-to-child transmission of HIV type 1: balancing the benefits and risks. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 48: 473-5. PMID 19133800 DOI: 10.1086/596489 |
0.457 |
|
| 2009 |
Ding M, Tarwater P, Rodriguez M, Chatterjee R, Ratner D, Yamamura Y, Roy P, Mellors J, Neogi D, Chen Y, Gupta P. Estimation of the predictive role of plasma viral load on CD4 decline in HIV-1 subtype C-infected subjects in India. Journal of Acquired Immune Deficiency Syndromes (1999). 50: 119-25. PMID 19131898 DOI: 10.1097/Qai.0B013E3181911991 |
0.49 |
|
| 2009 |
Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, Rao V, Coffin JM, Palmer S. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. Journal of Virology. 83: 2715-27. PMID 19116249 DOI: 10.1128/Jvi.01960-08 |
0.539 |
|
| 2008 |
Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Topics in Hiv Medicine : a Publication of the International Aids Society, Usa. 16: 266-85. PMID 19856548 |
0.479 |
|
| 2008 |
Mascolini M, Larder BA, Boucher CA, Richman DD, Mellors JW. Broad advances in understanding HIV resistance to antiretrovirals: report on the XVII International HIV Drug Resistance Workshop. Antiviral Therapy. 13: 1097-113. PMID 19195337 |
0.459 |
|
| 2008 |
Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry. 47: 14020-7. PMID 19067547 DOI: 10.1021/Bi8014778 |
0.805 |
|
| 2008 |
Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA, Lloyd M, Roby G, Kwan R, McLaughlin M, Stallings S, ... ... Mellors JW, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 29: 1009-21. PMID 19062316 DOI: 10.1016/J.Immuni.2008.10.010 |
0.524 |
|
| 2008 |
Hare CB, Mellors J, Krambrink A, Su Z, Skiest D, Margolis DM, Patel SS, Barnas D, Frenkel L, Coombs RW, Aweeka F, Morse GD, Haas DW, Boltz V, Palmer S, et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 47: 421-4. PMID 18558886 DOI: 10.1086/589867 |
0.511 |
|
| 2008 |
Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GC, Darko SW, Medina-Flores R, Murphey-Corb M, Rajakumar PA, Nyaundi J, Mellors JW, Bowser R, Wiley CA. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. The American Journal of Pathology. 173: 130-43. PMID 18556781 DOI: 10.2353/Ajpath.2008.080045 |
0.312 |
|
| 2008 |
Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 47: 266-85. PMID 18549313 DOI: 10.1086/589297 |
0.564 |
|
| 2008 |
Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, et al. Class-sparing regimens for initial treatment of HIV-1 infection. The New England Journal of Medicine. 358: 2095-106. PMID 18480202 DOI: 10.1056/Nejmoa074609 |
0.579 |
|
| 2008 |
Collier AC, Tierney C, Downey GF, Eshleman SH, Kashuba A, Klingman K, Vergis EN, Pakes GE, Rooney JF, Rinehart A, Mellors JW. Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. Hiv Clinical Trials. 9: 91-102. PMID 18474494 DOI: 10.1310/Hct0902-91 |
0.384 |
|
| 2008 |
Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America. 105: 3879-84. PMID 18332425 DOI: 10.1073/Pnas.0800050105 |
0.418 |
|
| 2008 |
Kearney M, Palmer S, Maldarelli F, Shao W, Polis MA, Mican J, Rock-Kress D, Margolick JB, Coffin JM, Mellors JW. Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. Aids (London, England). 22: 497-501. PMID 18301062 DOI: 10.1097/Qad.0B013E3282F29478 |
0.581 |
|
| 2008 |
Marchand C, Beutler JA, Wamiru A, Budihas S, Möllmann U, Heinisch L, Mellors JW, Le Grice SF, Pommier Y. Madurahydroxylactone derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and RNase H. Antimicrobial Agents and Chemotherapy. 52: 361-4. PMID 17967911 DOI: 10.1128/Aac.00883-07 |
0.471 |
|
| 2008 |
Zelina S, Sheen CW, Radzio J, Mellors JW, Sluis-Cremer N. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrobial Agents and Chemotherapy. 52: 157-63. PMID 17967907 DOI: 10.1128/Aac.00904-07 |
0.532 |
|
| 2007 |
Margolis DM, Mukherjee AL, Fletcher CV, Hogg E, Ogata-Arakaki D, Petersen T, Rusin D, Martinez A, Mellors JW. The use of β-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection Aids. 21: 2025-2032. PMID 17885292 DOI: 10.1097/Qad.0B013E3282364381 |
0.525 |
|
| 2007 |
Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. Plos One. 2: e875. PMID 17878928 DOI: 10.1371/Journal.Pone.0000875 |
0.534 |
|
| 2007 |
Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, Flanary L, Oswald K, Piatak M, Smedley J, Shao W, Bischofberger N, Maldarelli F, Kimata JT, Mellors JW, et al. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. Journal of Virology. 81: 12145-55. PMID 17855539 DOI: 10.1128/Jvi.01301-07 |
0.616 |
|
| 2007 |
Parikh UM, Zelina S, Sluis-Cremer N, Mellors JW. Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. Aids (London, England). 21: 1405-14. PMID 17589186 DOI: 10.1097/Qad.0B013E3281Ac229B |
0.568 |
|
| 2007 |
Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, Muñoz A. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 Cell count slope for progression to AIDS and death in untreated HIV-1 infection. Jama. 297: 2349-50. PMID 17551128 DOI: 10.1001/Jama.297.21.2349 |
0.523 |
|
| 2007 |
Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. Journal of Virology. 81: 7852-9. PMID 17507476 DOI: 10.1128/Jvi.02203-06 |
0.795 |
|
| 2007 |
Mascolini M, Boucher C, Larder B, Mellors J, Richman D. Key reports from the XV International HIV Drug Resistance Workshop 2006. Antiviral Therapy. 12: 131-45. PMID 17503758 |
0.489 |
|
| 2007 |
Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, ... ... Mellors JW, et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. Plos Pathogens. 3: e46. PMID 17411338 DOI: 10.1371/Journal.Ppat.0030046 |
0.592 |
|
| 2007 |
Garber M, Hanusa BH, Switzer GE, Mellors J, Arnold RM. HIV-infected African Americans are willing to participate in HIV treatment trials. Journal of General Internal Medicine. 22: 17-42. PMID 17351837 DOI: 10.1007/S11606-007-0121-8 |
0.56 |
|
| 2007 |
Schooley RT, Mellors JW. No cure yet for HIV-1, but therapeutic research presses on. The Journal of Infectious Diseases. 195: 770-2. PMID 17299705 DOI: 10.1086/511830 |
0.551 |
|
| 2007 |
Sluis-Cremer N, Sheen CW, Zelina S, Torres PS, Parikh UM, Mellors JW. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 51: 48-53. PMID 17088490 DOI: 10.1128/Aac.00683-06 |
0.523 |
|
| 2007 |
Boucher C, Larder B, Mellors J, Richman D. The XIVth International HIV Drug Resistance Workshop, Quebec City, Canada, June 2005. Antiviral Therapy. 11: 653-65. PMID 16964836 |
0.49 |
|
| 2006 |
McKinnon JE, Arribas JR, Pulido F, Delgado R, Mellors JW. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. Aids (London, England). 20: 2331-5. PMID 17117019 DOI: 10.1097/Qad.0B013E32801189F6 |
0.559 |
|
| 2006 |
Benson CA, Vaida F, Havlir DV, Downey GF, Lederman MM, Gulick RM, Glesby MJ, Wantman M, Bixby CJ, Rinehart AR, Snyder S, Wang R, Patel S, Mellors JW. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086. The Journal of Infectious Diseases. 194: 1309-18. PMID 17041858 DOI: 10.1086/508289 |
0.477 |
|
| 2006 |
Wiley CA, Lopresti BJ, Becker JT, Boada F, Lopez OL, Mellors J, Meltzer CC, Wisniewski SR, Mathis CA. Positron emission tomography imaging of peripheral benzodiazepine receptor binding in human immunodeficiency virus-infected subjects with and without cognitive impairment. Journal of Neurovirology. 12: 262-71. PMID 16966217 DOI: 10.1080/13550280600873868 |
0.51 |
|
| 2006 |
Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. Jama. 296: 806-14. PMID 16905786 DOI: 10.1001/Jama.296.7.806 |
0.351 |
|
| 2006 |
Parikh UM, Barnas DC, Faruki H, Mellors JW. Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level Journal of Infectious Diseases. 194: 651-660. PMID 16897664 DOI: 10.1086/505711 |
0.436 |
|
| 2006 |
Halvas EK, Aldrovandi GM, Balfe P, Beck IA, Boltz VF, Coffin JM, Frenkel LM, Hazelwood JD, Johnson VA, Kearney M, Kovacs A, Kuritzkes DR, Metzner KJ, Nissley DV, Nowicki M, ... ... Mellors JW, et al. Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. Journal of Clinical Microbiology. 44: 2612-4. PMID 16825395 DOI: 10.1128/Jcm.00449-06 |
0.373 |
|
| 2006 |
Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings Journal of Acquired Immune Deficiency Syndromes. 41: 632-641. PMID 16652038 DOI: 10.1097/01.Qai.0000194234.31078.Bf |
0.534 |
|
| 2006 |
Parikh UM, Bacheler L, Koontz D, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations Journal of Virology. 80: 4971-4977. PMID 16641288 DOI: 10.1128/Jvi.80.10.4971-4977.2006 |
0.509 |
|
| 2006 |
Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, Mellors J, Morris L, Coffin J. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proceedings of the National Academy of Sciences of the United States of America. 103: 7094-9. PMID 16641095 DOI: 10.1073/Pnas.0602033103 |
0.544 |
|
| 2006 |
Clark SA, Shulman NS, Bosch RJ, Mellors JW. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors Aids. 20: 981-984. PMID 16603849 DOI: 10.1097/01.Aids.0000222069.14878.44 |
0.52 |
|
| 2006 |
Palmer S, Boltz V, Maldarelli F, Kearney M, Halvas EK, Rock D, Falloon J, Davey RT, Dewar RL, Metcalf JA, Mellors JW, Coffin JM. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. Aids (London, England). 20: 701-10. PMID 16514300 DOI: 10.1097/01.Aids.0000216370.69066.7F |
0.585 |
|
| 2005 |
Nissley DV, Halvas EK, Hoppman NL, Garfinkel DJ, Mellors JW, Strathern JN. Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants. Journal of Clinical Microbiology. 43: 5696-704. PMID 16272507 DOI: 10.1128/Jcm.43.11.5696-5704.2005 |
0.527 |
|
| 2005 |
Hammond JL, Parikh UM, Koontz DL, Schlueter-Wirtz S, Chu CK, Bazmi HZ, Schinazi RF, Mellors JW. In vitro selection and analysis of human immunodeficiency virus type 1 resistant to derivatives of beta-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine. Antimicrobial Agents and Chemotherapy. 49: 3930-2. PMID 16127074 DOI: 10.1128/Aac.49.9.3930-3932.2005 |
0.591 |
|
| 2005 |
Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 366: 549-55. PMID 16099290 DOI: 10.1016/S0140-6736(05)67098-5 |
0.521 |
|
| 2005 |
Sluis-Cremer N, Arion D, Parikh U, Koontz D, Schinazi RF, Mellors JW, Parniak MA. The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. The Journal of Biological Chemistry. 280: 29047-52. PMID 15970587 DOI: 10.1074/Jbc.M503166200 |
0.551 |
|
| 2005 |
Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase Antimicrobial Agents and Chemotherapy. 49: 1139-1144. PMID 15728915 DOI: 10.1128/Aac.49.3.1139-1144.2005 |
0.589 |
|
| 2005 |
Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proceedings of the National Academy of Sciences of the United States of America. 102: 2093-8. PMID 15684061 DOI: 10.1073/Pnas.0409823102 |
0.607 |
|
| 2005 |
Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT, Dewar RL, Metcalf JA, Hammer S, Mellors JW, Coffin JM. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. Journal of Clinical Microbiology. 43: 406-13. PMID 15635002 DOI: 10.1128/Jcm.43.1.406-413.2005 |
0.385 |
|
| 2004 |
Tarwater PM, Gallant JE, Mellors JW, Gore ME, Phair JP, Detels R, Margolick JB, Muñoz A. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. Aids (London, England). 18: 2419-23. PMID 15622318 |
0.407 |
|
| 2004 |
Craigo JK, Patterson BK, Paranjpe S, Kulka K, Ding M, Mellors J, Montelaro RC, Gupta P. Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. Aids Research and Human Retroviruses. 20: 1196-209. PMID 15588342 DOI: 10.1089/Aid.2004.20.1196 |
0.606 |
|
| 2004 |
Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. Genetic correlates of efavirenz hypersusceptibility Aids. 18: 1781-1785. PMID 15316338 DOI: 10.1097/00002030-200409030-00006 |
0.392 |
|
| 2004 |
Achaz G, Palmer S, Kearney M, Maldarelli F, Mellors JW, Coffin JM, Wakeley J. A robust measure of HIV-1 population turnover within chronically infected individuals. Molecular Biology and Evolution. 21: 1902-12. PMID 15215321 DOI: 10.1093/Molbev/Msh196 |
0.432 |
|
| 2004 |
Velázquez S, Lobatón E, De Clercq E, Koontz DL, Mellors JW, Balzarini J, Camarasa MJ. Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond Journal of Medicinal Chemistry. 47: 3418-3426. PMID 15189038 DOI: 10.1021/Jm031045O |
0.471 |
|
| 2003 |
Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antiviral Therapy. 8: 507-18. PMID 14760884 |
0.417 |
|
| 2003 |
Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, Chodakewitz JA, Isaacs R, Gonzalez C, McMahon D, Richman DD, Robertson M, Mellors JW. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine Aids. 17: 2345-2349. PMID 14571186 DOI: 10.1097/00002030-200311070-00009 |
0.543 |
|
| 2003 |
Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. Journal of Clinical Microbiology. 41: 4531-6. PMID 14532178 DOI: 10.1128/Jcm.41.10.4531-4536.2003 |
0.541 |
|
| 2003 |
Wu H, Mellors J, Ruan P, McMahon D, Kelleher D, Lederman MM. Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors. Journal of Acquired Immune Deficiency Syndromes (1999). 33: 557-63. PMID 12902798 DOI: 10.1097/00126334-200308150-00002 |
0.563 |
|
| 2003 |
Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Richman DD. Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. Topics in Hiv Medicine : a Publication of the International Aids Society, Usa. 11: 150-4. PMID 12876334 |
0.391 |
|
| 2003 |
Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 37: 113-28. PMID 12830416 DOI: 10.1086/375597 |
0.599 |
|
| 2003 |
Meyer PR, Matsuura SE, Zonarich D, Chopra RR, Pendarvis E, Bazmi HZ, Mellors JW, Scott WA. Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. Journal of Virology. 77: 6127-37. PMID 12743270 DOI: 10.1128/Jvi.77.11.6127-6137.2003 |
0.566 |
|
| 2003 |
Montaner J, Mellors J. Meeting report from the 2nd International HIV Workshop on Management of Treatment-Experienced Patients. September 26-27 2002, San Diego, Calif., USA. Antiviral Therapy. S217-33. PMID 12699127 |
0.406 |
|
| 2003 |
Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D'Aquila RT, Van Gorder M, Holodniy M, Lloyd Jr RM, Reid C, Morgan GF, Winslow DL. Accuracy of the TRUGENE HIV-1 genotyping kit. Journal of Clinical Microbiology. 41: 1586-93. PMID 12682149 DOI: 10.1128/Jcm.41.4.1586-1593.2003 |
0.582 |
|
| 2002 |
Phair JP, Mellors JW, Detels R, Margolick JB, Muñoz A. Virologic and immunologic values allowing safe deferral of antiretroviral therapy Aids. 16: 2455-2459. PMID 12461420 DOI: 10.1097/00002030-200212060-00011 |
0.495 |
|
| 2002 |
Abbas UL, Mellors JW. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: Risk without reward Proceedings of the National Academy of Sciences of the United States of America. 99: 13377-13378. PMID 12370421 DOI: 10.1073/Pnas.212518999 |
0.578 |
|
| 2002 |
Pfister M, Labbé L, Lu JF, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB. Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clinical Pharmacology and Therapeutics. 72: 133-41. PMID 12189360 DOI: 10.1067/Mcp.2002.126183 |
0.469 |
|
| 2002 |
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. Antiretroviral-drug resistance among patients recently infected with HIV. The New England Journal of Medicine. 347: 385-94. PMID 12167680 DOI: 10.1056/Nejmoa013552 |
0.504 |
|
| 2002 |
Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, ... ... Mellors JW, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. Jama. 288: 169-80. PMID 12095381 DOI: 10.1001/Jama.288.2.169 |
0.329 |
|
| 2002 |
Meyer PR, Matsuura SE, Tolun AA, Pfeifer I, So AG, Mellors JW, Scott WA. Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 46: 1540-5. PMID 11959594 DOI: 10.1128/Aac.46.5.1540-1545.2002 |
0.416 |
|
| 2002 |
Schinazi RF, Mellors J, Bazmi H, Diamond S, Garber S, Gallagher K, Geleziunas R, Klabe R, Pierce M, Rayner M, Wu JT, Zhang H, Hammond J, Bacheler L, Manion DJ, et al. DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants. Antimicrobial Agents and Chemotherapy. 46: 1394-401. PMID 11959574 DOI: 10.1128/Aac.46.5.1394-1401.2002 |
0.73 |
|
| 2002 |
Harrold SM, Wang G, McMahon DK, Riddler SA, Mellors JW, Becker JT, Caldararo R, Reinhart TA, Achim CL, Wiley CA. Recovery of replication-competent HIV type 1-infected circulating monocytes from individuals receiving antiretroviral therapy. Aids Research and Human Retroviruses. 18: 427-34. PMID 11958686 DOI: 10.1089/088922202753614191 |
0.546 |
|
| 2002 |
Giorgi JV, Lyles RH, Matud JL, Yamashita TE, Mellors JW, Hultin LE, Jamieson BD, Margolick JB, Rinaldo CR, Phair JP, Detels R. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes (1999). 29: 346-55. PMID 11917238 DOI: 10.1097/00126334-200204010-00004 |
0.348 |
|
| 2002 |
Tang J, Shelton B, Makhatadze NJ, Zhang Y, Schaen M, Louie LG, Goedert JJ, Seaberg EC, Margolick JB, Mellors J, Kaslow RA. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. Journal of Virology. 76: 662-72. PMID 11752157 DOI: 10.1128/Jvi.76.2.662-672.2002 |
0.529 |
|
| 2001 |
Tarwater PM, Mellors J, Gore ME, Margolick JB, Phair J, Detels R, Muñoz A. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts American Journal of Epidemiology. 154: 675-681. PMID 11581102 DOI: 10.1093/Aje/154.7.675 |
0.432 |
|
| 2001 |
Gange SJ, Mellors JW, Lau B, Detels R, Phair JP, Muñoz A, Margolick JB. Longitudinal patterns of HIV type 1 RNA among individuals with late disease progression. Aids Research and Human Retroviruses. 17: 1223-9. PMID 11559421 DOI: 10.1089/088922201750461276 |
0.471 |
|
| 2001 |
Montaner JSG, Mellors JW. Antiretroviral therapy for previously treated patients New England Journal of Medicine. 345: 452-455. PMID 11496858 DOI: 10.1056/Nejm200108093450610 |
0.522 |
|
| 2001 |
McMahon D, Lederman M, Haas DW, Haubrich R, Stanford J, Cooney E, Horton J, Kelleher D, Ross L, Cutrell A, Lee D, Spreen W, Mellors JW. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults. Antiviral Therapy. 6: 105-14. PMID 11491415 |
0.489 |
|
| 2001 |
Yamashita TE, Phair JP, Muñoz A, Margolick JB, Detels R, O'Brien SJ, Mellors JW, Wolinsky SM, Jacobson LP. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study Aids. 15: 735-746. PMID 11371688 DOI: 10.1097/00002030-200104130-00009 |
0.452 |
|
| 2001 |
Hammond JL, Koontz DL, Bazmi HZ, Beadle JR, Hostetler SE, Kini GD, Aldern KA, Richman DD, Hostetler KY, Mellors JW. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance. Antimicrobial Agents and Chemotherapy. 45: 1621-8. PMID 11353603 DOI: 10.1128/Aac.45.6.1621-1628.2001 |
0.735 |
|
| 2001 |
Huang W, De Gruttola V, Fischl M, Hammer S, Richman D, Havlir D, Gulick R, Squires K, Mellors J. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. The Journal of Infectious Diseases. 183: 1455-65. PMID 11319681 DOI: 10.1086/320192 |
0.551 |
|
| 2001 |
Günthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eron J, Mellors J, Gulick R, Frost SD, Brown AJ, Schleif W, Valentine F, Jonas L, Meibohm A, Ignacio CC, Isaacs R, et al. Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. The Journal of Infectious Diseases. 183: 1318-27. PMID 11294662 DOI: 10.1086/319864 |
0.563 |
|
| 2001 |
Fan Z, Huang XL, Borowski L, Mellors JW, Rinaldo J. Restoration of anti-human immunodeficiency virus type 1 (HIV-1) responses in CD8+ T cells from late-stage patients on prolonged antiretroviral therapy by stimulation in vitro with HIV-1 protein-loaded dendritic cells Journal of Virology. 75: 4413-4419. PMID 11287592 DOI: 10.1128/Jvi.75.9.4413-4419.2001 |
0.576 |
|
| 2000 |
Vergis EN, Mellors JW. Natural history of HIV-1 infection Infectious Disease Clinics of North America. 14: 809-825. PMID 11144640 DOI: 10.1016/S0891-5520(05)70135-5 |
0.502 |
|
| 2000 |
Lederman MM, McKinnis R, Kelleher D, Cutrell A, Mellors J, Neisler M, Cooney E, Haas DW, Haubrich R, Stanford J, Horton J, Landay A, Spreen W. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. Aids (London, England). 14: 2635-42. PMID 11125881 DOI: 10.1097/00002030-200012010-00002 |
0.512 |
|
| 2000 |
Hostetler KY, Hammond JL, Kini GD, Hostetler SE, Beadle JR, Aldern KA, Chou TC, Richman DD, Mellors JW. In vitro anti-HIV-1 activity of sn-2-substituted 1-O-octadecyl-sn-glycero-3-phosphonoformate analogues and synergy with zidovudine. Antiviral Chemistry & Chemotherapy. 11: 213-9. PMID 10901292 DOI: 10.1177/095632020001100304 |
0.665 |
|
| 2000 |
Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, Valentine FT, McMahon D, Gonzalez C, Jonas L, Emini EA, Chodakewitz JA, Isaacs R, Richman DD. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Annals of Internal Medicine. 133: 35-9. PMID 10877738 DOI: 10.7326/0003-4819-133-1-200007040-00007 |
0.614 |
|
| 2000 |
Bazmi HZ, Hammond JL, Cavalcanti SC, Chu CK, Schinazi RF, Mellors JW. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. Antimicrobial Agents and Chemotherapy. 44: 1783-8. PMID 10858331 DOI: 10.1128/Aac.44.7.1783-1788.2000 |
0.701 |
|
| 2000 |
Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. Jama. 283: 2417-26. PMID 10815085 DOI: 10.1001/Jama.283.18.2417 |
0.59 |
|
| 2000 |
Mellors J, Montaner J. Salvage therapy for HIV-1 infection--the challenge grows. Lancet (London, England). 355: 1435. PMID 10791534 DOI: 10.1016/S0140-6736(05)74636-5 |
0.56 |
|
| 2000 |
Rinaldo CR, Huang XL, Fan Z, Margolick JB, Borowski L, Hoji A, Kalinyak C, Mcmahon DK, Riddler SA, Hildebrand WH, Day RB, Mellors JW. Anti-human immunodeficiency virus type 1 (HIV-1) CD8+ T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency Journal of Virology. 74: 4127-4138. PMID 10756025 DOI: 10.1128/Jvi.74.9.4127-4138.2000 |
0.574 |
|
| 2000 |
Lyles RH, Muñoz A, Yamashita TE, Bazmi H, Detels R, Rinaldo CR, Margolick JB, Phair JP, Mellors JW. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men Journal of Infectious Diseases. 181: 872-880. PMID 10720507 DOI: 10.1086/315339 |
0.582 |
|
| 2000 |
Huang XLI, Fan Z, Kalinyak C, Mellors JW, Rinaldo CR. CD8+ T-cell gamma interferon production specific for human immunodeficiency virus type 1 (HIV-1) in HIV-1-infected subjects Clinical and Diagnostic Laboratory Immunology. 7: 279-287. PMID 10702505 DOI: 10.1128/Cdli.7.2.279-287.2000 |
0.562 |
|
| 1999 |
Montaner JSG, Mellors JW. Effective salvage therapy for HIV-1 infection: An unmet challenge Antiviral Therapy. 4: 59-60. PMID 10682149 |
0.473 |
|
| 1999 |
Lyles RH, Tang AM, Smit E, Mellors JW, Margolick JB, Visscher BR, Phair JP, Graham NM. Virologic, immunologic, and immune activation markers as predictors of HIV-associated weight loss prior to AIDS. Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999). 22: 386-94. PMID 10634201 |
0.426 |
|
| 1999 |
Mellors JW. Adefovir for the treatment of HIV infection: If not now, when? Journal of the American Medical Association. 282: 2355-2356. PMID 10612325 DOI: 10.1001/Jama.282.24.2355 |
0.552 |
|
| 1999 |
Wiley CA, Achim CL, Christopherson C, Kidane Y, Kwok S, Masliah E, Mellors J, Radhakrishnan L, Wang G, Soontornniyomkij V. HIV mediates a productive infection of the brain. Aids (London, England). 13: 2055-9. PMID 10546857 DOI: 10.1097/00002030-199910220-00007 |
0.532 |
|
| 1999 |
Hirsch M, Steigbigel R, Staszewski S, Mellors J, Scerpella E, Hirschel B, Lange J, Squires K, Rawlins S, Meibohm A, Leavitt R. A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy. The Journal of Infectious Diseases. 180: 659-65. PMID 10438352 DOI: 10.1086/314948 |
0.526 |
|
| 1999 |
Mellors J. Testing time as resistant HIV-1 faces next wave of attack. Lancet (London, England). 354: 135. PMID 10408499 DOI: 10.1016/S0140-6736(05)75271-5 |
0.497 |
|
| 1999 |
Montaner J, Mellors J. Better salvage therapy for HIV-1 infection still needed. Lancet (London, England). 353: 1857. PMID 10359423 DOI: 10.1016/S0140-6736(99)00094-X |
0.562 |
|
| 1999 |
Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A, Nguyen BY, Chodakewitz J, Mellors J. Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. Aids Research and Human Retroviruses. 15: 499-508. PMID 10221527 DOI: 10.1089/088922299311024 |
0.429 |
|
| 1999 |
Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, Cohen C, Poretz D, Markowitz M, Follansbee S, Angel JB, McMahon D, Ho D, Devanarayan V, Rode R, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. Aids (London, England). 13: 213-24. PMID 10202827 DOI: 10.1097/00002030-199902040-00009 |
0.555 |
|
| 1999 |
Lyles RH, Chu C, Mellors JW, Margolick JB, Detels R, Giorgi JV, Al-Shboul Q, Phair JP, Armenian H, Farzadegan H, Kass N, McArthur J, Strathdee S, Taylor E. Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex Aids. 13: 341-349. PMID 10199224 DOI: 10.1097/00002030-199902250-00006 |
0.567 |
|
| 1999 |
Montaner J, Mellors J. Progress in HIV-1 therapy continues on upward track. Lancet (London, England). 353: 565. PMID 10028996 DOI: 10.1016/S0140-6736(05)75629-4 |
0.553 |
|
| 1999 |
Childs EA, Lyles RH, Selnes OA, Chen B, Miller EN, Cohen BA, Becker JT, Mellors J, McArthur JC. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 52: 607-13. PMID 10025796 DOI: 10.1212/Wnl.52.3.607 |
0.49 |
|
| 1999 |
Rinaldo CR, Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK, Day RD, Riddler SA, Mellors JW. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens Journal of Infectious Diseases. 179: 329-336. PMID 9878015 DOI: 10.1086/314599 |
0.529 |
|
| 1999 |
Kirstein LM, Mellors JW, Rinaldo CR, Margolick JB, Giorgi JV, Phair JP, Dietz E, Gupta P, Sherlock CH, Hogg R, Montaner JSG, Muñoz A. Effects of Anticoagulant, Processing Delay, and Assay Method (Branched DNA versus Reverse Transcriptase PCR) on Measurement of Human Immunodeficiency Virus Type 1 RNA Levels in Plasma Journal of Clinical Microbiology. 37: 2428-2433. DOI: 10.1128/Jcm.37.8.2428-2433.1999 |
0.495 |
|
| 1999 |
Lyles RH, Tang AM, Smit E, Mellors JW, Margolick JB, Visscher BR, Phair JP, Graham NMH. Virologic, immunologic, and immune activation markers as predictors of HIV-associated weight loss prior to AIDS Journal of Acquired Immune Deficiency Syndromes. 22: 386-394. DOI: 10.1097/00042560-199912010-00010 |
0.484 |
|
| 1998 |
Tramontano E, Piras G, Mellors JW, Putzolu M, Bazmi HZ, La Colla P. Biochemical characterization of HIV-1 reverse transcriptases encoding mutations at amino acid residues 161 and 208 involved in resistance to phosphonoformate Biochemical Pharmacology. 56: 1583-1589. PMID 9973178 DOI: 10.1016/S0006-2952(98)00206-8 |
0.57 |
|
| 1998 |
Saah AJ, Hoover DR, Weng S, Carrington M, Mellors J, Rinaldo CR, Mann D, Apple R, Phair JP, Detels R, O'Brien S, Enger C, Johnson P, Kaslow RA. Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection Aids. 12: 2107-2113. PMID 9833851 DOI: 10.1097/00002030-199816000-00005 |
0.546 |
|
| 1998 |
Tachedjian G, Mellors JW, Bazmi H, Mills J. Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1 Aids Research and Human Retroviruses. 14: 1059-1064. PMID 9718121 DOI: 10.1089/Aid.1998.14.1059 |
0.524 |
|
| 1998 |
Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Jonas L, Meibohm A, Holder D, Schleif WA, Condra JH, Emini EA, Isaacs R, Chodakewitz JA, Richman DD. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up Journal of the American Medical Association. 280: 35-41. PMID 9660361 DOI: 10.1001/Jama.280.1.35 |
0.575 |
|
| 1998 |
Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. Jama. 279: 1984-91. PMID 9643863 DOI: 10.1001/Jama.279.24.1984 |
0.549 |
|
| 1998 |
Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L- 2',3'-dideoxy-3'-thiacytidine Journal of Virology. 72: 5093-5098. PMID 9573280 DOI: 10.1128/Jvi.72.6.5093-5098.1998 |
0.42 |
|
| 1998 |
Wiley CA, Soontornniyomkij V, Radhakrishnan L, Masliah E, Mellors J, Hermann SA, Dailey P, Achim CL. Distribution of brain HIV load in AIDS. Brain Pathology (Zurich, Switzerland). 8: 277-84. PMID 9546286 DOI: 10.1111/J.1750-3639.1998.Tb00153.X |
0.528 |
|
| 1997 |
Riddler SA, Mellors JW. HIV-1 viral load and clinical outcome: review of recent studies Aids (London, England). 11. PMID 9451978 |
0.384 |
|
| 1997 |
Shi C, Mellors JW. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors Antimicrobial Agents and Chemotherapy. 41: 2781-2785. PMID 9420060 DOI: 10.1128/Aac.41.12.2781 |
0.599 |
|
| 1997 |
Riddler SA, Mellors JW. HIV-1 viral dynamics and viral load measurement: implications for therapy Aids Clinical Review. 47-65. PMID 9305443 |
0.419 |
|
| 1997 |
Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA, Deutsch P, Holder D, Schleif WA, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy New England Journal of Medicine. 337: 734-739. PMID 9287228 DOI: 10.1056/Nejm199709113371102 |
0.571 |
|
| 1997 |
Rosowsky A, Fu H, Pai N, Mellors J, Richman DD, Hostetler KY. Synthesis and in vitro activity of long-chain 5'-O- [(alkoxycarbonyl)phosphinyl]-3'axido-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1 Journal of Medicinal Chemistry. 40: 2482-2490. PMID 9258355 DOI: 10.1021/Jm970172F |
0.426 |
|
| 1997 |
Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection Annals of Internal Medicine. 126: 946-954. PMID 9182471 DOI: 10.7326/0003-4819-126-12-199706150-00003 |
0.511 |
|
| 1997 |
Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J, Stool E, Jemsek JG, Dellamonica P, Cross A, Dunkle L. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double- blind, controlled trial Annals of Internal Medicine. 126: 355-363. PMID 9054279 DOI: 10.7326/0003-4819-126-5-199703010-00003 |
0.492 |
|
| 1997 |
Gupta P, Mellors J, Kingsley L, Riddler S, Singh MK, Schreiber S, Cronin M, Rinaldo CR. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. Journal of Virology. 71: 6271-6275. DOI: 10.1128/Jvi.71.8.6271-6275.1997 |
0.535 |
|
| 1997 |
Rosowsky A, Fu H, Pai N, Mellors J, Richman D, Hostetler K. Synthesis and in vitro antiviral activity of long-chain 5′-O-alkoxycarbonylphosphinyl)-3′-azido-3′-deoxythymidines against drug-sensitive and AZT- or PFA-resistant human immunodeficiency virus type-1 (HIV-1) Antiviral Research. 34: A43. DOI: 10.1016/S0166-3542(97)83150-6 |
0.511 |
|
| 1997 |
Mellors JW. Best predictor of disease prognosis in HIV-infected patients Consultant. 37: 2777. |
0.439 |
|
| 1997 |
Mellors JW. Decreasing viral load to improve patient survival: a review of recent clinical data Antiviral Therapy. 2: 17-20. |
0.475 |
|
| 1996 |
Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, ... ... Mellors JW, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. Journal of Virology. 70: 8270-6. PMID 8970946 DOI: 10.1128/Jvi.70.12.8270-8276.1996 |
0.509 |
|
| 1996 |
Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma Science. 272: 1167-1170. PMID 8638160 DOI: 10.1126/Science.272.5265.1167 |
0.517 |
|
| 1996 |
Graham NM, Hoover DR, Park LP, Stein DS, Phair JP, Mellors JW, Detels R, Saah AJ. Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS Cohort Study Group. Annals of Internal Medicine. 124: 1031-8. PMID 8633816 DOI: 10.7326/0003-4819-124-12-199606150-00002 |
0.44 |
|
| 1996 |
Griffith BP, Brett-Smith H, Kim G, Mellors JW, Chacko TM, Garner RB, Cheng YC, Alcabes P, Friedland G. Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. The Journal of Infectious Diseases. 173: 1252-5. PMID 8627080 DOI: 10.1093/Infdis/173.5.1252 |
0.485 |
|
| 1996 |
Mellors JW. Closing in on human immunodeficiency virus-1 Nature Medicine. 2: 274-275. PMID 8612219 DOI: 10.1038/Nm0396-274 |
0.317 |
|
| 1996 |
Tachedjian G, Mellors J, Bazmi H, Birch C, Mills J. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. Journal of Virology. 70: 7171-7181. DOI: 10.1128/Jvi.70.10.7171-7181.1996 |
0.498 |
|
| 1995 |
Riddler SA, Anderson RE, Mellors JW. Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, D4T) Antiviral Research. 27: 189-203. PMID 8540743 DOI: 10.1016/0166-3542(95)00016-F |
0.467 |
|
| 1995 |
Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion Annals of Internal Medicine. 122: 573-579. PMID 7887550 DOI: 10.7326/0003-4819-122-8-199504150-00003 |
0.53 |
|
| 1995 |
Medina DJ, Tung PP, Lerner-Tung MB, Nelson CJ, Mellors JW, Strair RK. Sanctuary growth of human immunodeficiency virus in the presence of 3'- azido-3'-deoxythymidine Journal of Virology. 69: 1606-1611. PMID 7853495 |
0.556 |
|
| 1995 |
Tachedjian G, Hooker DJ, Gurusinghe AD, Bazmi H, Deacon NJ, Mellors J, Birch C, Mills J. Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1. Virology. 212: 58-68. PMID 7545854 DOI: 10.1006/Viro.1995.1453 |
0.58 |
|
| 1995 |
Mellors JW, Bazmi HZ, Schinazi RF, Roy BM, Hsiou Y, Arnold E, Weir J, Mayers DL. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates Antimicrobial Agents and Chemotherapy. 39: 1087-1092. PMID 7542860 DOI: 10.1128/Aac.39.5.1087 |
0.62 |
|
| 1995 |
Gupta P, Ding M, Cottrill M, Rinaldo C, Kingsley L, Wolinsky S, Mellors J. Quantitation of human immunodeficiency virus type 1 DNA and RNA by a novel internally controlled PCR assay. Journal of Clinical Microbiology. 33: 1670-1673. DOI: 10.1128/Jcm.33.6.1670-1673.1995 |
0.566 |
|
| 1995 |
Riddler SA, Mellors JW. Use of stavudine therapy for HIV infection Current Opinion in Infectious Diseases. 8: 483-488. DOI: 10.1097/00001432-199512000-00015 |
0.548 |
|
| 1995 |
Tramontano E, Piras G, Congeddu E, Mellors J, Bazmi H, La Colla P. Characterization of HIV-1 reverse transcriptase encoding mutations at the amino acid residues 161 and 208 involved in phosphonoformate resistance Antiviral Research. 26: A268. DOI: 10.1016/0166-3542(95)94777-Y |
0.555 |
|
| 1995 |
Mellors JW, Larder BA, Schinazi RF. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance International Antiviral News. 3: 8-13. |
0.508 |
|
| 1994 |
Nguyen MH, Schinazi RF, Shi C, Goudgaon NM, McKenna PM, Mellors JW. Resistance of human immunodeficiency virus type 1 to acyclic 6- phenylselenenyl- and 6-phenylthiopyrimidines Antimicrobial Agents and Chemotherapy. 38: 2409-2414. PMID 7840579 |
0.47 |
|
| 1994 |
Mellors JW, Strair RK. A recombinant HIV encoding beta-galactosidase permits quantitation of rare drug-resistant infection of target cells International Antiviral News. 2: 21-22. |
0.419 |
|
| 1993 |
Strair RK, Median DJ, Nelson CJ, Graubert TA, Mellors JW. Recombinant retroviral systems for the analysis of drug resistant HIV Nucleic Acids Research. 21: 4836-4842. PMID 8233833 DOI: 10.1093/Nar/21.20.4836 |
0.552 |
|
| 1993 |
Schinazi RF, Lloyd RM, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ, Mellors JW. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents and Chemotherapy. 37: 875-81. PMID 7684216 DOI: 10.1128/Aac.37.4.875 |
0.582 |
|
| 1993 |
Mellors JW, Im GJ, Tramontano E, Winkler SR, Medina DJ, Dutschman GE, Bazmi HZ, Piras G, Gonzalez CJ, Cheng YC. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150). Molecular Pharmacology. 43: 11-6. PMID 7678690 |
0.528 |
|
| 1992 |
Beenhouwer DO, Rankin JA, Mellors JW. Anti-HIV-1 activity of 3′-azido-3′-deoxythymidine (AZT) in primary mononuclear phagocytes Antiviral Research. 19: 43-54. PMID 1444321 DOI: 10.1016/0166-3542(92)90055-A |
0.37 |
|
| 1991 |
Mellors JW, Griffith BP, Ortiz MA, Landry ML, Ryan JL. Tumor necrosis factor-α/cachectin enhances human immunodeficiency virus type 1 replication in primary macrophages Journal of Infectious Diseases. 163: 78-82. PMID 1984479 |
0.44 |
|
| 1991 |
Medina D, Hsiung G, Mellors J. Ganciclovir antagonizes the anti-HIV-1 activity of zidovudine in vitro Antiviral Research. 15: 115. DOI: 10.1016/0166-3542(91)90221-C |
0.47 |
|
| 1989 |
Griffith BP, Ferguson D, Mellors JW. Acute Human Immunodeficiency Virus Infection: False-Negative Elisa in A Patient With Viremia and A Positive Western Blot Test Journal of Infectious Diseases. 160: 160-161. PMID 2732510 DOI: 10.1093/Infdis/160.1.160 |
0.318 |
|
| Show low-probability matches. |